Supplementary Information (SI) for Organic & Biomolecular Chemistry. This journal is © The Royal Society of Chemistry 2025

Cu-catalyzed Photoredox

Chlorotrifluoromethylation of Polysubstituted Alkenes and Pharmacological Evaluation

Supporting Information

Shauna Barreto^{a,b}, Renaud Binette^b, Alexandre Murza^b, Jean Legault^c, André Pichette^c, Pierre-Luc Boudreault^{b*}, Samuel Couve-Bonnaire^{a*}, Thomas Castanheiro^a

^aUniv. Rouen Normandie, INSA Rouen Normandie, CNRS, Normandie Univ., Institut CARMeN UMR 6064, INC3M FR 3038, F-76000 Rouen, France ^bDe´partement de Pharmacologie-Physiologie, Faculte´ de Me´decine et des Sciences de la Sante´, and Institut de Pharmacologie de Sherbrooke, Universite´ de Sherbrooke, Sherbrooke, J1H 5N4, QC, Canada ^cDépartement des Sciences Fondamentales, Université du Québec at Chicoutimi, Chicoutimi, G7H 2B1, QC, Canada

Email: pierre-luc.boudreault@usherbrooke.ca, samuel.couve-bonnaire@insa-rouen.fr,

thomas.castanheiro-matias@univ-rouen.fr

Table of contents

1.	General informations
2.	Materials
3.	General procedures
a.	General procedure A for synthesis of amides 1
b	General procedure B for synthesis of amides 3 4
c.	General procedure C for synthesis of amides 5 4
d	General procedure D for chlorotrifluoromethylation of polysubstituted alkenes 2, 4 and 6
a	5
4.	
	5 Biological Activity Assessment
4.	5 Biological Activity Assessment
4. a.	5 Biological Activity Assessment
4. a. b.	5 Biological Activity Assessment

1. General informations

Photoredox reactions were performed with HepatoChem lamps into cardboard box with a distance of 8 cm between the lamps and reactions and a stirring at 1000 rpm. All reactions were carried out using an oven-dried 5 mL borosilicate flask and magnetic stirring under air unless otherwise stated. When needed, reactions were heated with a sand bath. Column chromatographies were carried out using silica gel (40-63 µm) supplied by VWR or Merck PTLC on silica gel 60 F254, 2 mm. Analytical thin layer chromatographies were performed on pre-coated silica gel aluminum plates with F-254 indicator (from Merck) and visualized by UV light (254 nm) and/or chemical stained with a KMnO₄ solution. ¹H (300 MHz), ¹³C (75 MHz) and ¹⁹F (282 MHz) NMR spectra were recorded on a Bruker DXP 300 MHz spectrometer in CDCl₃ unless otherwise noted. Chemical shifts (δ) are quoted in ppm relative to the residual solvent peak for CDCl₃ (¹H: $\delta_{\rm H}$ = 7.26 ppm and ¹³C: δ_c = 77.16 ppm) and relative to the external standard CFCl₃ (¹⁹F: δ_F = 0.00 ppm). ¹H (400 MHz), ¹³C (101 MHz) and ¹⁹F (377 MHz) NMR spectra were recorded on a Bruker Avance III 400 MHz spectrometer in CDCl₃ or $(CD_3)_2SO$ unless otherwise noted. Chemical shifts (δ) are quoted in ppm relative to the residual solvent peak for CDCl₃ (¹H: $\delta_{\rm H}$ = 7.26 ppm and ¹³C: $\delta_{\rm C}$ = 77.16 ppm) or $(CD_3)_2$ SO (1H: δ_H = 2.50 and 13 C: δ_C = 39.52 ppm). Coupling constants (*J*) are quoted in Hz. The following abbreviations were used to show multiplicities: s = singlet, d = doublet, t = doublettriplet, m = multiplet, q = quarter, p = pentet, dd = doublet of doublets, dt = doublet of triplets, dq = doublet of quartets, tt = triplet of triplets, brs = broad singlet. High-resolution mass (HRMS) were carried out on a Waters LCP Premier XR spectrometer with a TOF analyzer or were acquired on a maXis 3G (ESI-QqTOF) orthogonal mass spectrometer from Bruker Daltonik (Bremen, Germany) using electrospray ionization in positive (or negative) ion mode. Each compound was dissolved in dichloromethane (or methanol) then diluted 10-fold in methanol and infused individually into the ESI-QqTOFMS using a syringe pump at a flow rate of 5μ L/min. Mass spectra were recorded in the range m/z 50-1200 and external calibration was performed using a sodium formate 0.5 mM solution. IR spectra were recorded on a PerkinElmer FT-IR Spectrum 100 (ATR), the wave numbers (n) of recorded IR-signals (ATR) are quoted in cm⁻¹.

The copper complex [Cu(dap)₂]Cl was prepared according to literature.^[1]

The minor diastereoisomer was characterized only when it could be isolated and the diastereoisomeric ratio was determined by ¹⁹F NMR on crude product, before any treatment or purification.

2. Materials

Anhydrous acetonitrile (MeCN), anhydrous acetone ((Me)₂CO), methanol (MeOH), ethanol (EtOH), dimethyl sulfoxide (DMSO) and *N*,*N*-dimethylformamide (DMF) were purchased from Acros Organics (Solvents Extra Dry Over Molecular Sieve, AcroSeal®). Dichloromethane (DCM) was purified by distillation over CaH₂. Tetrahydrofuran (THF) was distilled over sodium/benzophenone prior to use.

Cinnamic acid, cinnamic acid derivatives, oxalyl chloride, aniline, benzylamine, methylamine, *tert*butylamine, aqueous ammonia, phenylacetaldehyde, phenylacetaldehyde derivatives, malonic acid, triethylamine (TEA), 1-3-dimethylaminopropyl-3-ethylcarbodiimide hydrochloride (EDCI), hexafluorophosphate azabenzotriazole tetramethyl uronium (HATU), *N*,*N*-diisopropylethylamine (DIPEA), benzaldehyde, benzaldehyde derivatives, vinylmagnesium bromide, triethyl orthoacetate (MeC(OEt)₃), phenol (PhOH), 1,1'-carbonyldiimidazole (CDI), glycine methyl ester hydrochloride, trifluoromethanesulfonyl chloride (F₃CSO₂Cl) were purchased from Fisher Scientific, Sigma Aldrich, aaBlocks, Combiblock and were used without any purification steps.


3. General procedures

a. General procedure A for synthesis of amides 1

$$R^{1}\frac{I}{U} \longrightarrow OH \qquad \underbrace{1) (COCI)_2, DMF, DCM, 0 °C, 1 h}_{2) R^2 NH_2, DCM, 0 °C, 45 min} \qquad \underbrace{R^{1}\frac{I}{U}}_{I} \qquad \underbrace{R^{1}\frac{I}{U}}_{$$


According to literature procedure^[2] An anhydrous DCM (50 mM) solution of oxalyl chloride (7.80 mmol, 1.3 equiv.) was added slowly to a DCM (150 mM) solution of the appropriate carboxylic acid (6.00 mmol, 1.0 equiv.) and DMF (0.90 mmol, 0.1 equiv.) at 0 °C. The reaction mixture was stirred at 0 °C for 1 h, and the solvent was then evaporated under reduced pressure to give the corresponding cinnamoyl chloride. In a round-bottom flask was placed the corresponding amine in DCM (1 M). The solution was cooled to 0 °C and then cinnamoyl chloride was added in portion while stirring. After addition, the mixture was stirred for 45 min at room temperature and then water was added. The solution was extracted 3 times with DCM. The organic layers were collected together, dried over MgSO₄, and concentrated under reduced pressure. The crude product was recrystallized from DCM/Pentane.

b. General procedure B for synthesis of amides 3



Benzaldehyde (7.45 mmol, 1.0 equiv.) and malonic acid (8.20 mmol, 1.1 equiv.) were dissolved in Et₃N (4 M). The reaction mixture was refluxed for 4 h and then cooled to room temperature. Then, diethyl ether was added to the reaction mixture, and acidified with 10% HCl to pH = 1, the organic layer was separated and washed with 5% NaOH solution, the aqueous layer was extracted with diethyl ether and the organic layer was discarded (to remove the organic impurities). The aqueous layer was acidified again with 10% HCl solution, extracted with ether. The combined organic layers were dried over MgSO₄ and concentrated under vacuum. The crude product was used for the next step without purification. A mixture of the corresponding carboxylic acid (7.00 mmol, 1.0 equiv.), amide (7.70 mmol, 1.1 equiv.), EDCI (7.70 mmol, 1.1 equiv.) and DIPEA (21.00 mmol, 3.0 equiv.) in DCM (500 mM) was stirred for overnight at room temperature. Water was added to the solution and the aqueous layer was extracted 3 times with DCM. The combined organic layers were washed with water, brine, dried with Na₂SO₄ and concentrated under reduced pressure. The crude product was recrystallized from DCM/Pentane.

c. General procedure C for synthesis of amides 5




To a solution of benzaldehyde (8.32 mmol, 1.0 equiv.) in anhydrous THF (500 mM) under an atmosphere of argon at 0 °C was added, vinyl magnesium bromide (9.15 mmol, 1.1 equiv., 1 M sol in THF). The reaction was stirred at 0 °C for 30 min and then allowed to react at room temperature for 3 h. The solution was diluted with Et_2O , poured into a separating funnel and quenched with a saturated aqueous solution of NH_4Cl . After phase separation, the aqueous layer was extracted 3 times with Et_2O . The combined organic layers were washed with brine, dried over MgSO₄ and concentrated under reduced pressure. The crude phenylprop-2-enol was directly used for the next step without purification.

To a stirred solution of phenylprop-2-enol (6.09 mmol, 1.0 equiv.) in MeC(OEt)₃ (12.79 mmol, 2.1 equiv.) was added phenol (0.61 mmol, 0.1 equiv.) and the mixture was heated at 160 °C for 15 h in a Dean-Stark apparatus. After this time, the remaining MeC(OEt)₃ was distilled off, and a 2.5 M solution of NaOH in 10% H₂O/MeOH (15 mL) was added. The mixture was heated to reflux for 1 h at 100 °C. The mixture was then cooled to room temperature and diluted with a 1 M NaOH aqueous solution. The aqueous layer was extracted twice with DCM, then acidified with a 4 M HCl aqueous solution. The aqueous layer was extracted 5 times with DCM. The combined organic layers were dried over MgSO₄ and concentrated under reduced pressure. The crude product was recrystallized from DMC/Pentane.

To a mixture of the corresponding carboxylic acid (0.64 mmol, 1.0 equiv.) and HATU (0.71 mmol, 1.1 equiv.) in DMF (100 mM) at 0 °C was added aniline (0.71 mmol, 1.1 equiv.) and DIPEA (3.86 mmol, 6.0 equiv.). The solution was stirred for 25 min at room temperature. AcOEt was added to the solution and the mixture was washed 5 times with water. The organic layer was dried with Na₂SO₄ and concentrated under reduced pressure. The crude product was recrystallized with DCM/Pentane.

d. General procedure D for chlorotrifluoromethylation of polysubstituted alkenes 2, 4 and 6



An oven-dried 5 mL borosilicate vial equipped with a rubber septum was charged with the corresponding amide (0.30 mmol, 1.0 equiv.), Cu(dap)₂Cl (1 mol%) and Na₂HPO₄ (0.60 mmol, 2.0 equiv.). Acetone (333 mM) was degassed by three freeze-pump-thaw cycles and added to the reagents followed by the addition of the triflyl chloride (F₃CSO₂Cl) (0.60 mmol, 2.0 equiv.). The reaction mixture was irradiated for 4 h with green light (λ_{max} = 530nm) at room temperature from a distance of approximately 8 cm. Afterwards, the reaction mixture was filtered through cotton and concentrated under reduced pressure. The crude was purified by silica gel column chromatography and eluting with the appropriate solvent mixture to afford **2**, **4** and **6**.

4. Biological Activity Assessment a. Antibacterial and Antifungal Assays

According to reported procedure,^[3] antibacterial activity was evaluated using a microdilution method. Briefly, exponentially growing bacteria were plated in 96-well microplates (Costar, Corning Inc.) at a density of 5×103 gram-negative *E. coli* (ATCC 25922) or 3.5×104 gram-positive *S. aureus* (ATCC 25923) per well in 100 µL nutrient broth (Difco), or 2×103 *C. albicans* (ATCC 10231) per well in 100 µL sabouraud dextrose (Difco). Increasing concentrations of compounds (solubilized in biotech DMSO, then diluted in nutrient broth or sabouraud dextrose) were then added (100 µL per well). The final concentration of DMSO in the culture medium was maintained at 0.1% (volume/volume) to avoid solvent toxicity. Absorbance was read after 24h incubation using a Varioskan Ascent plate reader (Thermo Electron) at 600 nm for bacteria and 540 nm for yeasts.

	IC90 (μM)					
Cpds	E. coli	S. aureus	C.albicans			
		83 ± 12 (IC50 = 68 ± 10				
2a	>200	μΜ)	>200 (IC50 = 84 ± 13 µM)			
2c	>200	>200	>200			
2e	>200	>200	>200			
2g	>200	>200	>200			
2h	>200	>200	>200			
2j	>200	>200	>200			
2m	>200	>200	>200 >200 >200			
2n	>200	>200				
20	>200	>200				
4a	>200	>200	>200			
4b	>200	>200	>200			
4f	>200	>200	>200			
6a	>200	>200	>200			
4h	>200	>200 (IC50 = 131 ± 5 µM)	>200			
6d	>200	>200	>200			
6f	>200	>200	>200			
6g	>200	>200 (IC50 = 26 ± 6 µM)	>200			
6h	>200	>200 (IC50 = 30 ± 3 µM)	>200			
	0.088 ± 0.009 (IC50 =	0.034 ± 0.004 (IC50 =				
Gentamicin	0.054 ± 0.006 μg/ml)	0,013 ± 0,002 μg/ml)				
			0.18 ± 0.01 (IC50 = 0.12 ±			
AmphotericinB			0.01 μM)			

Table 1: Antibacterial and antifungal activity of analogs.

Note: IC90/IC50: concentration of compounds inhibiting bacteria growth by 90%/50%. Gentamicin and Amphotericin B are used as standard.

b. Cytotoxicity assay

According to reported procedure,^[4] The A-549 human lung carcinoma (CCL-185), DLD-1 human colorectal adenocarcinoma (CCL-221), and WS-1 skin fibroblast (CRL-1502) cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). Exponentially growing cells were plated in 96-well microplates (Costar, Corning Inc.) at a density of 5x103 cells per well in 100 μ L of culture medium (DMEM supplemented with 10% fetal bovine serum, vitamins 1X, penicillin, and streptomycin) and were allowed to adhere for 16 h before treatment. A concentration gradient of each compound was prepared in biotech DMSO (Sigma–Aldrich) and then diluted in DMEM before it was added to microplates (100 μ L per well). Cells were then incubated for 48 h. The final concentration of DMSO in the culture medium was maintained at 0.5% (v/v) to avoid solvent toxicity. Cytotoxicity was assessed using resazurin and Hoechst (bis-


benzimide H-33342) on an automated Fluoroskan Ascent F1TM plate reader (Labsystems) using excitation and emission wavelengths of 530 and 590 nm and 358 and 461 nm respectively for each fluorochrom. Survival percentage was defined as the fluorescence in experimental wells compared to that in control wells after the subtraction of blank values. It is expressed as the concentration of compounds inhibiting cell growth by 50% (IC50).

	ΙC50 (μΜ)						
	Resazurine	Resazurine	Resazurine	Hoechst	Hoechst	Hoechst	
Cpds	A-549	DLD-1	WS-1	A-549	DLD-1	WS-1	
2a	5.6 ± 0.7	4.2 ± 0.3	6.9 ± 0.1	9 ± 2	6.0 ± 0.7	15 ± 3	
2c	>200	>200	>200	>200	>200	>200	
2e	31 ± 3	18.5 ± 0.3	52 ± 4	49 ± 10	21 ± 4	80 ± 8	
2g	20 ± 2	12.8 ± 0.5	28 ± 1	29 ± 8	14 ± 2	69 ± 10	
2h	16.6 ± 0.6	7.1 ± 0.2	18.5 ± 0.9	18 ± 1	9±1	29 ± 5	
2j	102 ± 7	39 ± 5	115 ± 8	98 ± 10	60 ± 10	169 ± 11	
2m	12.2 ± 0.6	3.5 ± 0.2	8 ± 1	12.4 ± 0.9	4.3 ± 0.9	9±1	
2n	6.1 ± 0.5	2.46 ± 0.03	6.7 ± 0.1	9 ± 1	3 ± 1	8.6 ± 0.6	
20	6.5 ± 0.6	2.37 ± 0.02	4.7 ± 0.4	3 ± 1	2.8 ± 0.6	7.0 ± 0.9	
4a	>200	>200	>200	>200	>200	>200	
4b	>200	>200	>200	>200	>200	>200	
4 f	>200	>200	>200	>200	>200	>200	
6a	>200	>200	>200	>200	>200	>200	
4h	>200	>200	>200	>200	>200	>200	
6 d	>200	>200	>200	171 ± 10	>200	>200	
6f	>200	>200	>200	>200	>200	>200	
6g	>200	>200	>200	>200	>200	>200	
6h	>200	>200	>200	>200	>200	>200	
	0.084 ±	0.071 ±	0.116 ±	0.051 ±	0.044 ±	0.31 ±	
Daunorubicin	0.005	0.003	0.008	0.006	0.006	0.06	


Table 2: Cytotoxic activity of analogs.

Note: Resazurine and Hoechst are two dyes and represent two different methods of detection. A-549: human lung carcinoma cell line (CCL-185). DLD-1: human colorectal adenocarcinoma cell line (CCL-221). WS-1: skin fibroblast cell line (CRL-1502).


5. Characterization of products




N-(phenyl)cinnamamide 1a was synthesized from commercial cinnamic acid and aniline following general procedure A. 1a was obtained as white powder (879.1 mg, 69% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.76 (d, *J* = 15.5 Hz, 1H), 7.63 (d, *J* = 6.9 Hz, 2H), 7.53 (m, 2H), 7.37 (m, 6H), 7.14 (t, *J* = 7.4 Hz, 1H), 6.56 (d, *J* = 15.5 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃): δ 164.4, 142.5, 138.2, 134.7, 130.0, 129.2, 129.0, 128.1, 124.6, 121.1, 120.2. The NMR data correspond to those described in literature.^[5]




N-(benzyl)cinnamamide 1b was synthesized from commercial cinnamic acid and benzylamine following general procedure A. 1b was obtained as white powder (1.2 g, 72% yield). ¹H NMR (300 MHz, CDCl₃): δ 7.67 (d, *J* = 15.6 Hz, 1H), 7.51 – 7.47 (m, 2H), 7.37 – 7.30 (m, 8H), 6.43 (d, *J* = 15.6 Hz, 1H), 6.05 (brs, 1H), 4.57 (d, *J* = 5.8 Hz, 2H). ¹³C NMR (75 MHz, CDCl₃): δ 165.9, 141.5, 138.3, 134.9, 129.8, 128.9, 128.9, 128.1, 127.9, 127.7, 120.6, 44.0. The NMR data correspond to those described in literature.^[6]




N-(methyl)cinnamamide 1c was synthesized from commercial cinnamic acid and methylamine following general procedure A. 1c was obtained as white powder (454.3 mg, 36% yield). ¹H NMR (300 MHz, CDCl₃): δ 7.63 (d, *J* = 15.6 Hz, 1H), 7.50 – 7.47 (m, 2H), 7.36 – 7.33 (m, 3H), 6.41 (d, *J* = 15.6 Hz, 1H), 5.88 (brs, 1H), 2.94 (d, *J* = 4.9 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃): δ 166.8, 140.9, 135.0, 129.7, 128.9, 127.9, 120.7, 26.7. The NMR data correspond to those described in literature.^[7]



N-(*tert*-butyl)cinnamamide 1d was synthesized from commercial cinnamic acid and *tert*butylamine following general procedure A. 1d was obtained as white powder (1.0 g, 84% yield). ¹H NMR (300 MHz, CDCl₃): δ 7.57 (d, *J* = 15.5 Hz, 1H), 7.49 – 7.46 (m, 2H), 7.39 – 7.32 (m, 3H), 6.32 (d, *J* = 15.5 Hz, 1H), 5.46 (s, 1H), 1.43 (s, 9H). ¹³C NMR (75 MHz, CDCl₃): δ 165.3, 140.4, 135.1, 129.6, 128.9, 127.8, 122.1, 51.7, 29.0. The NMR data correspond to those described in literature.^[6]




Cinnamamide 1e was synthesized from commercial cinnamic acid and ammonium hydroxide (NH₄OH) following general procedure A. **1e** was obtained as white powder (10.1 g, 80% yield). ¹**H NMR** (400 MHz, (CD₃)₂SO): δ 7.55 (d, *J* = 7.3 Hz, 3H), 7.44 (d, *J* = 16.0 Hz, 1H), 7.38 – 7.34 (m, 3H), 7.16 (brs, 1H), 6.63 (d, *J* = 16.0 Hz, 1H). ¹³**C NMR** (101 MHz, (CD₃)₂SO): δ 166.8, 139.2, 134.9, 129.5, 128.9, 127.6, 122.3. The NMR data correspond to those described in literature.^[6]




Carbonyldiimidazole (CDI) (411.0 mg, 2.53 mmol, 1.2 equiv.) was added in a suspension of cinnamic acid (313.0 mg, 2.11 mmol, 1.0 equiv.) in acetonitrile (10 mL, 210 mM) and the vial was sealed with a screw cap. The suspension became quickly transparent and was stirred at room temperature for 45 min on the orbital shaker. After this, the vial was unsealed and degassed to slowly add glycine methyl ester hydrochloride (318.0 mg, 2.53 mmol, 1.2 equiv.) and was resealed for another 4 h at room temperature on the orbital shaker. After the reaction completion, the mixture was concentrated at reduced pressure to remove acetonitrile before being resolubilized in ethyl acetate and transferred in a separatory funnel. The organic layer was washed two times with 1 M aqueous NaOH solution and 2 times with 1 M aqueous HCl solution before being dried with MgSO₄ and concentrated under reduced pressure to give methyl 2-cinnamamidoacetate **1f** as white solid (426.0 mg, 92% yield). **1H NMR** (400 MHz, CDCl₃): δ 7.64 (d, *J* = 15.7 Hz, 1H), 7.49 – 7.46 (m, 2H), 7.34 – 7.33 (m, 3H), 6.52 – 6.48 (m, 2H), 4.18 (d, *J* = 5.2 Hz, 2H), 3.76 (s, 3H). **1³C NMR**

(101 MHz, CDCl₃): δ 170.7, 166.2, 141.9, 134.7, 129.9, 128.9, 128.0, 119.9, 52.5, 41.6. The NMR data correspond to those described in literature.^[8]


4-(methyl)cinnamamide 1g was synthesized from commercial (*E*)-3-(*p*-tolyl)acrylic acid and ammonium hydroxide (NH₄OH) following general procedure A. **1g** was obtained as white powder (977.1 mg, 99% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.63 (d, *J* = 15.7 Hz, 1H), 7.42 (d, *J* = 8.1 Hz, 2H), 7.19 (d, *J* = 8.1 Hz, 2H), 6.41 (d, *J* = 15.7 Hz, 1H), 5.57 (brs, 2H), 2.37 (s, 3H). ¹³C NMR (101 MHz, (CD₃)₂SO): δ 167.3, 139.6, 139.5, 132.2, 129.7, 127.7, 121.2, 21.1. HRMS (ESI+) m/z: calcd for C₁₀H₁₁NaNO [M+Na]⁺: 184.0733, found 184.0733 (Δ = 0.0 ppm). IR (neat, cm⁻¹): ν 3302, 3150, 1680, 1600, 1400, 1250.




3-(methyl)cinnamamide 1h was synthesized from commercial (*E*)-3-(*m*-tolyl)acrylic acid and ammonium hydroxide (NH₄OH) following general procedure A. **1h** was obtained as white powder (944.3 mg, 95% yield). ¹H NMR (400 MHz, (CD₃)₂SO): δ 7.59 (brs, 1H), 7.40 – 7.29 (m, 3H), 7.27 (t, *J* = 7.5 Hz, 1H), 7.17 (d, *J* = 7.5 Hz, 1H), 7.13 (brs, 1H), 6.61 (d, *J* = 15.9 Hz, 1H), 2.30 (s, 3H). ¹³C NMR (101 MHz, (CD₃)₂SO): δ 167.1, 139.6, 138.3, 134.9, 130.4, 129.0, 128.2, 125.0, 122.1, 21.0. HRMS (ESI+) m/z: calcd for C₁₀H₁₁NaNO [M+Na]⁺: 184.0733, found 184.0741 (Δ = 4.3 ppm). **IR** (neat, cm⁻¹): v 3390, 3195, 1640, 1605, 1400, 1260.




2-(methyl)cinnamamide 1i was synthesized from commercial (*E*)-3-(*o*-tolyl)acrylic acid and ammonium hydroxide (NH₄OH) following general procedure A. **1i** was obtained as white powder (963.1 mg, 97% yield). ¹H NMR (400 MHz, (CD₃)₂SO): δ 7.66 (d, *J* = 15.5 Hz, 2H), 7.53 (m, 1H), 7.27 – 7.19 (m, 3H), 7.16 (brs, 1H), 6.52 (d, *J* = 15.5 Hz, 1H), 2.35 (s, 3H). ¹³C NMR (101 MHz, (CD₃)₂SO): δ 167.2, 137.0, 136.9, 133.8, 130.8, 129.4, 126.5, 126.1, 123.4, 19.5. HRMS (ESI+) m/z: calcd for C₁₀H₁₁NaNO [M+Na]⁺: 184.0733, found 184.0735 (Δ = 1.1 ppm). **IR** (neat, cm⁻¹): ν 3390, 3197, 1680, 1600, 1390, 1240.




4-(methoxy)cinnamamide 1j was synthesized from commercial (*E*)-3-(*p*-methoxyphenyl)acrylic acid and ammonium hydroxide (NH₄OH) following general procedure A. **1j** was obtained as white powder (937.6 mg, 95% yield). ¹H NMR (400 MHz, (CD₃)₂SO): δ 7.57 (brs, 1H), 7.50 (d, *J* = 8.5 Hz, 2H), 7.37 (dd, *J* = 15.8, 4.9 Hz, 1H), 7.06 (brs, 1H), 6.96 (dd, *J* = 8.5, 2.9 Hz, 2H), 6.49 (dd, *J* = 15.8, 6.8 Hz, 1H), 3.75 (s, 3H). ¹³C NMR (101 MHz, (CD₃)₂SO): δ 167.5, 160.5, 139.3, 129.4, 127.5, 119.8, 114.5, 55.4. HRMS (ESI+) m/z: calcd for C₁₀H₁₁NaNO₂ [M+Na]+: 200.0682, found 200.0682 (Δ = 0.0 ppm). **IR** (neat, cm⁻¹): v 3450, 3360, 3150, 2910, 1660, 1595, 1500, 1400, 1270.




4-(dimethylamino)cinnamamide 1k was synthesized from commercial (*E*)-3-(*p*-(dimethylamino)phenyl)acrylic acid and ammonium hydroxide (NH₄OH) following general procedure A. 1k was obtained as beige powder (648.9 mg, 58% yield). ¹H NMR (300 MHz, (CD₃)₂SO): δ 7.47 – 7.43 (m, 4H), 6.67 (d, *J* = 8.9 Hz, 2H), 6.21 (d, *J* = 15.8 Hz, 1H), 2.94 (s, 6H). ¹³C NMR (75 MHz, (CD₃)₂SO): δ 168.2, 151.6, 144.7, 129.8, 121.6, 113.0, 111.8. The NMR data correspond to those described in literature.^[9]




4-(formyl)cinnamamide 11 was synthesized from commercial (*E*)-3-(*p*-formylphenyl)acrylic acid and ammonium hydroxide (NH₄OH) following general procedure A. **11** was obtained as orange powder (706.3 mg, 72% yield). ¹**H NMR** (400 MHz, (CD₃)₂SO): δ 10.01 (s, 1H), 7.93 (d, *J* = 8.1 Hz, 2H), 7.77 (d, *J* = 8.1 Hz, 2H), 7.64 (brs, 1H), 7.49 (d, *J* = 15.9 Hz, 1H), 7.25 (brs, 1H), 6.77 (d, *J* = 15.9 Hz, 1H). ¹³**C NMR** (101 MHz, (CD₃)₂SO): δ 192.6, 166.2, 140.7, 137.9, 136.4, 130.0, 128.2, 125.5. The NMR data correspond to those described in literature.^[10]




4-(methoxycarbonyl)cinnamamide 1m was synthesized from commercial (*E*)-3-(*p*-(methoxycarbonyl)phenyl)acrylic acid and ammonium hydroxide (NH₄OH) following general procedure A. **1m** was obtained as white powder (690.4 mg, 95% yield). **¹H NMR** (400 MHz, (CD₃)₂SO): δ 7.95 (m, 2H), 7.68 (m, 3H), 7.46 (d, *J* = 15.9 Hz, 1H), 7.23 (brs, 1H), 6.73 (d, *J* = 15.9 Hz, 1H), 3.83 (s, 3H). ¹³C NMR (101 MHz, (CD₃)₂SO): δ 166.6, 166.0, 139.6, 138.2, 130.1, 129.9, 128.0, 125.0, 52.4. HRMS (ESI+) m/z: calcd for C₁₁H₁₁NaNO₃ [M+Na]+: 228.0631, found 228.0632 (Δ = 0.4 ppm). **IR** (neat, cm⁻¹): v 3400, 3170, 1700, 1680, 1601, 1390, 1295.




4-(cyano)cinnamamide 1n was synthesized from commercial (*E*)-3-(*p*-cyanophenyl)acrylic acid and ammonium hydroxide (NH₄OH) following general procedure A. **1n** was obtained as beige powder (825.1 mg, 83% yield). **¹H NMR** (400 MHz, (CD₃)₂SO): δ 7.87 (d, *J* = 8.3 Hz, 2H), 7.75 (d, *J* = 8.3 Hz, 2H), 7.64 (brs, 1H), 7.47 (d, *J* = 15.9 Hz, 1H), 7.25 (brs, 1H), 6.75 (d, *J* = 15.9 Hz, 1H). ¹³**C NMR** (101 MHz, (CD₃)₂SO): δ 166.0, 139.6, 137.3, 132.8, 128.2, 125.9, 118.7, 111.4. **HRMS** (ESI+) m/z: calcd for C₁₀H₈NaN₂O [M+Na]⁺: 195.0529, found 195.0531 (Δ = 1.0 ppm). **IR** (neat, cm⁻¹): ν 3490, 3170, 2220, 1660, 1600, 1395.




4-(trifluoromethyl)cinnamamide 10 was synthesized from commercial (*E*)-3-(*p*-(trifluoromethyl)phenyl)acrylic acid and ammonium hydroxide (NH₄OH) following general procedure A. **10** was obtained as white powder (894.6 mg, 89% yield). ¹H NMR (400 MHz, (CD₃)₂SO): δ 7.78 – 7.69 (m, 5H), 7.48 (d, *J* = 15.9 Hz, 1H), 7.25 (brs, 1H), 6.75 (d, *J* = 15.9 Hz, 1H). ¹³C NMR (101 MHz, (CD₃)₂SO): δ 166.6, 139.0, 137.9, 129.4 (q, *J* = 32.0 Hz), 128.4, 125.9 (q, *J* = 3.3 Hz), 125.2, 124.2 (q, *J* = 272.1 Hz). ¹⁹F NMR (377 MHz, (CD₃)₂SO): δ -66.36. HRMS (ESI+) m/z: calcd for C₁₀H₈F₃NaNO [M+Na]⁺: 238.0450, found 238.0452 (Δ = 0.8 ppm). IR (neat, cm⁻¹): v 3330, 3155, 1660, 1600, 1390, 1305, 1100.




3-(trifluoromethyl)cinnamamide 1p was synthesized from commercial (*E*)-3-(*m*-(trifluoromethyl)phenyl)acrylic acid and ammonium hydroxide (NH₄OH) following general procedure A. **1p** was obtained as white powder (814.6 mg, 84% yield). ¹**H** NMR (400 MHz, CDCl₃): δ 7.73 (s, 1H), 7.71 – 7.55 (m, 3H), 7.48 – 7.44 (m, 1H), 6.57 (d, *J* = 15.7 Hz, 1H), 6.45 (brs, 1H), 6.09 (brs, 1H). ¹³**C** NMR (75 MHz, CDCl₃): δ 167.2, 140.8, 135.3, 131.4 (q, *J* = 32.6 Hz), 131.3, 129.4, 126.4 (q, *J* = 7.0 Hz), 124.1 (q, *J* = 3.8 Hz), 123.8 (q, *J* = 272.5 Hz), 121.4. ¹⁹**F** NMR (282 MHz, CDCl₃): δ -63.38. **HRMS** (ESI+) m/z: calcd for C₁₀H₈F₃NaNO [M+Na]⁺: 238.0450, found 238.0453 (Δ = 1.2 ppm). **IR** (neat, cm⁻¹): v 3320, 3160, 1660, 1600, 1400, 1320, 1110.




(*E*)-hex-2-enamide 1q was synthesized from commercial (*E*)-pent-2-enoic acid and aniline following general procedure A. 1r was obtained as white powder (942.5 mg, 88% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.57 (d, *J* = 7.1 Hz, 3H), 7.31 (t, *J* = 7.9 Hz, 2H), 7.10 (t, *J* = 7.3 Hz, 1H), 7.03 (dt, *J* = 15.2, 6.4 Hz, 1H), 5.94 (m, 1H), 2.30 – 2.18 (m, 2H), 1.07 (t, *J* = 7.3 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 164.4, 148.0, 138.2, 129.1, 124.3, 123.2, 120.1, 25.3, 12.5. The NMR data correspond to those described in literature.^[11]




3-phenylpropiolamide 1t was synthesized from commercial 3-phenylpropiolic acid and ammonium hydroxide (NH₄OH) following general procedure A. **1t** was obtained as white powder (796.8 mg, 79% yield). ¹**H NMR** (400 MHz, CDCl₃): δ 7.56 (d, *J* = 1.2 Hz, 1H), 7.54 (d, *J* = 1.5 Hz, 1H), 7.51 – 7.33 (m, 3H), 5.88 (brs, 2H). ¹³**C NMR** (101 MHz, CDCl₃): δ 155.0, 132.8, 130.5, 128.7, 120.1, 86.2, 82.4. **HRMS** (ESI+) m/z: calcd for C₉H₇NaNO [M+Na]⁺: 168.0420, found 168.0420 (Δ = 0.0 ppm). **IR** (neat, cm⁻¹): v 3360, 3190, 2205, 1600, 1490, 1390.




(*E*)-4-(*p*-tolyl)but-3-enoic acid S3f was synthesized from commercial (*p*-tolyl)acetaldehyde following general procedure B. S3f was obtained as beige powder (990.0 mg, 75% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.27 (d, *J* = 8.0 Hz, 2H), 7.12 (d, *J* = 8.0 Hz, 2H), 6.49 (d, *J* = 15.9 Hz, 1H), 6.23 (dt, *J* = 15.9, 7.1 Hz, 1H), 3.29 (dd, *J* = 7.1, 1.2 Hz, 2H), 2.33 (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 177.8, 137.7, 134.0, 129.4, 126.4, 119.9, 38.1, 21.3. HRMS (ESI+) m/z: calcd for C₁₁H₁₂NaO₂ [M+Na]+: 199.0730, found 199.0726 (Δ = 2.0 ppm). IR (neat, cm⁻¹): v 2910, 1710, 1510, 1400, 1300, 1200.




(*E*)-4-(*p*-methoxyphenyl)but-3-enoic acid S3g was synthesized from commercial (*p*-methoxyphenyl)acetaldehyde following general procedure B. S3g was obtained as beige powder (770.4 mg, 61% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.31 (dt, *J* = 8.7, 2.1 Hz, 2H), 6.85 (dt, *J* = 8.7, 2.1 Hz, 2H), 6.46 (d, *J* = 15.9 Hz, 1H), 6.14 (dt, *J* = 15.9, 7.1 Hz, 1H), 3.81 (s, 3H), 3.28 (dd, *J* = 7.1, 1.4 Hz, 2H). ¹³C NMR (101 MHz, CDCl₃): δ 177.7, 159.4, 133.6, 129.6, 127.6, 118.7, 114.1, 55.4, 38.1. HRMS (ESI+) m/z: calcd for C₁₁H₁₂NaO₃ [M+Na]⁺: 215.0679, found 215.0677 (Δ = 0.9 ppm). IR (neat, cm⁻¹): v 2910, 1700, 1600, 1500, 1250, 1150.




(*E*)-4-(*p*-(trifluoromethyl)phenyl)but-3-enoic acid S3h was synthesized from commercial (*p*-(trifluoromethyl)phenyl)acetaldehyde following general procedure B. S3h was obtained as beige powder (220.4 mg, 18% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.57 (d, *J* = 8.2 Hz, 2H), 7.47 (d, *J* = 8.2 Hz, 2H), 6.56 (d, *J* = 16.0 Hz, 1H), 6.39 (dt, *J* = 16.0, 7.0 Hz, 1H), 3.34 (dd, *J* = 7.0, 1.2 Hz, 2H). ¹³C NMR (101 MHz, CDCl₃): δ 177.7, 140.2 (d, *J* = 1.2 Hz), 132.9, 129.7 (q, *J* = 32.5 Hz), 127.8 (q, *J* = 271.8 Hz), 126.6, 125.7 (q, *J* = 3.8 Hz), 123.7, 38.0. ¹⁹F NMR (377 MHz, CDCl₃): δ -63.04. HRMS (ESI-) m/z: calcd for C₁₁H₉F₃O₂ [M-H]⁻: 229.0482, found 229.0474 (Δ = 3.5 ppm). IR (neat, cm⁻¹): ν 2920, 1700, 1410, 1310, 1160, 1100, 1050.




N-**phenyl-4**-**phenylbut-3**-**enamide 3a** was synthesized from commercial *trans*-styrylacetic acid and aniline following general procedure B. **3a** was obtained as beige powder (1.5 g, 88% yield). ¹H NMR (300 MHz, CDCl₃): δ 7.52 – 7.28 (m, 10H), 7.11 (t, *J* = 7.4 Hz, 1H), 6.64 (d, *J* = 15.9 Hz, 1H), 6.39 (dt, *J* = 15.9, 7.3 Hz, 1H), 3.34 (dd, *J* = 7.3, 1.1 Hz, 2H). ¹³C NMR (75 MHz, CDCl₃): δ 168.9, 137.8, 136.5, 135.6, 129.1, 128.8, 128.2, 126.5, 124.6, 122.0, 120.0, 42.1. The NMR data correspond to those described in literature.^[12]



N-benzyl-4-phenylbut-3-enamide 3b was synthesized from commercial *trans*-styrylacetic acid and benzylamine following general procedure B. 3b was obtained as beige powder (558.1 mg, 36% yield). ¹H NMR (300 MHz, CDCl₃): δ 7.39 – 7.25 (m, 10H), 6.54 (d, *J* = 15.9 Hz, 1H), 6.31 (dt, *J* = 15.9, 7.2 Hz, 1H), 5.94 (brs, 1H), 4.46 (d, *J* = 5.8 Hz, 2H), 3.22 (dd, *J* = 7.2, 1.0 Hz, 2H). ¹³C NMR (75 MHz, CDCl₃): δ 170.6, 138.3, 136.6, 135.0, 128.9, 128.8, 128.0, 127.9, 127.7, 126.5, 122.3, 43.9, 41.0, 34.1. The NMR data correspond to those described in literature.^[12]




N-méthyl-4-phenylbut-3-enamide 3c was synthesized from commercial *trans*-styrylacetic acid and methylamine following general procedure B. 3c was obtained as beige powder (444.3 mg, 20% yield). ¹H NMR (300 MHz, CDCl₃): δ 7.40 – 7.25 (m, 5H), 6.53 (d, *J* = 15.9 Hz, 1H), 6.29 (dt, *J* = 15.9, 7.3 Hz, 1H), 5.70 (brs, 1H), 3.16 (d, *J* = 7.3 Hz, 2H), 2.82 (d, *J* = 4.9 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃): δ 171.4, 136.6, 135.0, 128.8, 128.0, 126.4, 122.5, 40.9, 26.6. The NMR data correspond to those described in literature.^[13]




N-(*tert*-butyl)-4-phenylbut-3-enamide 3d was synthesized from commercial *trans*-styrylacetic acid and *tert*-butylamine following general procedure B. 3d was obtained as beige powder (1.1 g, 90% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.39 (m, 2H), 7.37 – 7.30 (m, 2H), 7.24 (m, 1H), 6.51 (d, *J*


= 15.8 Hz, 1H), 6.29 (dt, *J* = 15.8, 7.3 Hz, 1H), 5.38 (brs, 1H), 3.08 (dd, *J* = 7.3, 1.3 Hz, 2H), 1.35 (s, 9H). ¹³C NMR (101 MHz, CDCl₃): δ 170.1, 136.9, 134.4, 128.7, 127.8, 126.4, 123.1, 51.5, 42.1, 28.9. The NMR data correspond to those described in literature.^[14]




4- phenylbut-3-enamide 3e was synthesized from commercial *trans*-styrylacetic acid and ammonium hydroxide (NH₄OH) following general procedure B. **3e** was obtained as white powder (1.5 g, 75% yield). ¹H NMR (300 MHz, CDCl₃): δ 7.42 – 7.25 (m, 5H), 6.57 (d, *J* = 15.9 Hz, 1H), 6.33 (dt, *J* = 15.9, 7.3 Hz, 1H), 5.81 (brs, 1H), 5.72 (brs, 1H), 3.20 (dd, *J* = 7.3, 1.0 Hz, 2H). ¹³C NMR (75 MHz, CDCl₃): δ 173.3, 136.5, 134.7, 128.6, 127.9, 126.3, 122.2, 40.2. The NMR data correspond to those described in literature.^[15]




N-phenyl-4-(*p*-tolyl)but-3-enamide 3f was synthesized from (*E*)-4-(*p*-tolyl)but-3-enoic acid S3f and aniline following general procedure B. 3f was obtained as beige powder (42.2 mg, 30% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.50 (d, *J* = 7.8 Hz, 2H), 7.36 – 7.2 (m, 5H), 7.16 (d, *J* = 7.8 Hz, 2H), 7.11 (t, *J* = 7.4 Hz, 1H), 6.61 (d, *J* = 15.9 Hz, 1H), 6.33 (dt, *J* = 15.9, 7.3 Hz, 1H), 3.32 (dd, *J* = 7.3, 0.9 Hz, 2H), 2.35 (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 169.1, 138.1, 137.8, 135.7, 133.7, 129.5, 129.2, 126.5, 124.6, 120.8, 120.0, 42.1, 21.4. HRMS (ESI+) m/z: calcd for C₁₇H₁₇NaNO [M+Na]+: 274.1202, found 274.1209 (Δ = 2.6 ppm). **IR** (neat, cm⁻¹): v 3280, 2902, 1647, 1610, 1440.




4-(4-methoxyphenyl)-*N*-phenylbut-3-enamide 3g was synthesized from (*E*)-4-(*p*-methoxyphenyl)but-3-enoic acid S3g and aniline following general procedure B. 3g was obtained as beige powder (45.0 mg, 18% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.50 (d, *J* = 8.0 Hz, 2H), 7.36 – 7.29 (m, 5H), 7.11 (t, *J* = 7.4 Hz, 1H), 6.88 (d, *J* = 8.7 Hz, 2H), 6.58 (d, *J* = 15.8 Hz, 1H), 6.23 (dt, *J* = 15.8, 7.2 Hz, 1H), 3.82 (s, 3H), 3.31 (d, *J* = 7.2 Hz, 2H). ¹³C NMR (101 MHz, CDCl₃): δ 168.8, 159.4, 137.5, 134.9, 129.0, 128.8, 127.4, 124.3, 119.7, 119.2, 113.9, 55.2, 41.8. HRMS (ESI+) m/z: calcd for C₁₇H₁₇NaNO₂ [M+Na]+: 290.1151, found 290.1157 (Δ = 2.1 ppm). IR (neat, cm⁻¹): v 3285, 2910, 1660, 1600, 1510, 1250, 1180.



N-phenyl-4-(4-(trifluoromethyl)phenyl)but-3-enamide 3f was synthesized from (*E*)-4-(*p*-(trifluoromethyl)phenyl)but-3-enoic acid S3h and aniline following general procedure B. 3f was obtained as beige powder (20.0 mg, 18% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.59 (d, *J* = 8.2 Hz, 2H), 7.52 – 7.49 (m, 4H), 7.33 (t, *J* = 7.4 Hz, 3H), 7.12 (t, *J* = 7.4 Hz, 1H), 6.65 (d, *J* = 16.0 Hz, 1H), 6.51 (dt, *J* = 16.0, 7.1 Hz, 1H), 3.36 (d, *J* = 7.1 Hz, 2H). ¹³C NMR (101 MHz, CDCl₃): δ 168.4, 140.0, 137.6, 133.8, 129.6 (q, *J* = 30.3 Hz), 129.2, 126.7, 125.8 (q, *J* = 4.0 Hz), 124.9, 124.8, 124.2 (q, *J* = 274.9 Hz), 120.0, 41.9. ¹⁹F NMR (377 MHz, CDCl₃): δ -63.07. HRMS (ESI+) m/z: calcd for $C_{17}H_{14}F_3NaNO$ [M+Na]⁺: 328.0920, found 328.0932 (Δ = 3.7 ppm). IR (neat, cm⁻¹): v 3300, 2920, 1690, 1510, 1320, 1160, 1110, 1070.




(*E*)-5-(*p*-tolyl)pent-4-enoic acid S5e was synthesized from commercial 4-methylbenzaldehyde following general procedure C. S5e was obtained as beige powder (128.4 mg, 48% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.24 (d, *J* = 8.1 Hz, 2H), 7.10 (d, *J* = 8.1 Hz, 2H), 6.42 (d, *J* = 15.8 Hz, 1H), 6.21 – 6.12 (m, 1H), 2.54 (m, 4H), 2.33 (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 179.0, 137.1, 134.6, 131.2, 130.4, 129.3, 127.1, 126.1, 33.9, 28.1, 21.3. HRMS (ESI+) m/z: calcd for C₁₂H₁₄NaO₂ [M+Na]⁺: 213.0886, found 213.0885 (Δ = 0.4 ppm). IR (neat, cm⁻¹): v 2950, 2850, 1700, 1610, 1512, 1435.




MeO


(*E*)-5-(4-methoxyphenyl)pent-4-enoic acid S5f was synthesized from commercial 4methoxybenzaldehyde following general procedure C. S5f was obtained as beige powder (461.3 mg, 37% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.27 (d, *J* = 8.7 Hz, 2H), 6.84 (d, *J* = 8.7 Hz, 2H), 6.39 (d, *J* = 15.8 Hz, 1H), 6.15 – 6.01 (m, 1H), 3.80 (s, 3H), 2.53 (s, 4H). ¹³C NMR (101 MHz, CDCl₃): δ 178.9, 159.1, 130.7, 130.2, 127.3, 125.9, 114.1, 55.4, 34.0, 28.1. HRMS (ESI+) m/z: calcd for C₁₂H₁₄NaO₃ [M+Na]⁺: 229.0835, found 229.0842 (Δ = 3.1 ppm). IR (neat, cm⁻¹): v 2940, 1698, 1600, 1510, 1250, 1180, 1040.




(*E*)-5-(4-(trifluoromethyl)phenyl)pent-4-enoic acid S5g was synthesized from commercial 4-(trifluoromethyl)benzaldehyde following general procedure C. S5g was obtained as beige powder (682.9 mg, 75% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.54 (d, *J* = 8.2 Hz, 2H), 7.43 (d, *J* = 8.2 Hz, 2H), 6.48 (d, *J* = 15.8 Hz, 1H), 6.36 – 6.28 (m, 1H), 2.57 (d, *J* = 3.0 Hz, 4H). ¹³C NMR (101 MHz, CDCl₃): δ 178.8, 141.1, 131.2, 130.5, 129.5 (q, *J* = 32.4 Hz), 126.7, 125.9 (q, *J* = 3.8 Hz), 124.7 (q, *J* = 271.9 Hz), 33.8, 28.3. ¹⁹F NMR (377 MHz, CDCl₃): δ -62.98. HRMS (ESI+) m/z: calcd for $C_{12}H_{11}F_3NaO_2$ [M+Na]+: 267.0603, found 267.0614 (Δ = 4.1 ppm). IR (neat, cm⁻¹): v 2920, 1700, 1310, 1180, 1105, 1070.




(*E*)-5-(4-chlorophenyl)pent-4-enoic acid S5h was synthesized from commercial 4chlorobenzaldehyde following general procedure C. S5h was obtained as beige powder (724.0 mg, 69% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.30 (m, 5H), 6.44 (d, *J* = 15.8 Hz, 1H), 6.30 – 6.17 (m, 1H), 2.59 (s, 2H), 2.58 (s, 2H). ¹³C NMR (101 MHz, CDCl₃): δ 178.3, 135.9, 133.0, 130.2, 128.8, 128.8, 127.4, 33.6, 28.0. HRMS (ESI+) m/z: calcd for C₁₁H₁₁³⁵ClNaO₂ [M+Na]⁺: 233.0340, found 233.0334 (Δ = 2.6 ppm). IR (neat, cm⁻¹): v 2905, 1700, 1500, 1090, 800.




N-5-diphenylpent-4-enamide 5a was synthesized from commercial (*E*)-5-phenylpent-4-enoic acid and aniline following general procedure C. 5a was obtained as beige powder (714.0 mg, 66% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.52 (m, 3H), 7.35 – 7.27 (m, 6H), 7.21 (tt, *J* = 6.7, 1.7 Hz, 1H), 7.11 (t, *J* = 7.4 Hz, 1H), 6.47 (d, *J* = 15.8 Hz, 1H), 6.25 (dt, *J* = 15.8, 6.7 Hz, 1H), 2.64 (q, *J* = 7.2 Hz, 2H), 2.52 (m, 2H). ¹³C NMR (101 MHz, CDCl₃): δ 170.7, 138.0, 137.3, 131.4, 129.1, 128.6, 128.6, 127.3, 126.2, 124.4, 120.1, 37.3, 28.9. The NMR data correspond to those described in literature.^[16]




N-(**benzyl**)-**5**-**phenylpent**-**4**-**enamide 5b** was synthesized from commercial (*E*)-5-phenylpent-4enoic acid and benzylamine following general procedure C. **5b** was obtained as beige powder (484.8 mg, 89% yield). ¹H NMR (300 MHz, CDCl₃): δ 7.31 – 7.16 (m, 10H), 6.45 (d, *J* = 15.8 Hz, 1H), 6.30 – 6.11 (dt, *J* = 15.8, 6.9 Hz, 1H), 5.74 (brs, 1H), 4.46 (d, *J* = 5.7 Hz, 2H), 2.60 (q, *J* = 7.0 Hz, 2H), 2.39 (t, *J* = 7.3 Hz, 2H). ¹³C NMR (75 MHz, CDCl₃): δ 172.1, 138.4, 137.4, 131.3, 128.8, 128.7, 128.6, 127.9, 127.6, 127.3, 126.2, 43.7, 36.5, 29.1. The NMR data correspond to those described in literature.^[17]



N-(methyl)-5-phenylpent-4-enamide 5c was synthesized from commercial (*E*)-5-phenylpent-4-enoic acid and methylamine following general procedure C. 5c was obtained as beige powder (647.4 mg, 80% yield). ¹H NMR (300 MHz, CDCl₃): δ 7.35 – 7.29 (m, 4H), 7.23 – 7.18 (m, 1H), 6.44 (d, *J* = 15.9 Hz, 1H), 6.21 (dt, *J* = 15.9, 6.8 Hz, 1H), 5.45 (brs, 1H), 2.82 (d, *J* = 4.9 Hz, 3H), 2.56 (q, *J* = 7.4 Hz, 2H), 2.34 (t, *J* = 7.4 Hz, 2H). ¹³C NMR (75 MHz, CDCl₃): δ 173.0, 137.4, 131.0, 128.9, 128.6, 127.2, 126.1, 36.3, 29.1, 26.4. The NMR data correspond to those described in literature.^[18]




N-(*tert*-butyl)-5-phenylpent-4-enamide 5d was synthesized from commercial (*E*)-5-phenylpent-4-enoic acid and *tert*-butylamine following general procedure C. 5d was obtained as beige powder (443.5 mg, 93% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.34 – 7.27 (m, 4H), 7.22 – 7.18 (tt, *J* = 6.9, 2.2 Hz, 1H), 6.43 (d, *J* = 15.8 Hz, 1H), 6.20 (dt, *J* = 15.8, 6.9 Hz, 1H), 5.34 (brs, 1H), 2.57 – 2.47 (dq, *J* = 6.9, 1.2 Hz, 2H), 2.25 (t, *J* = 7.4 Hz, 2H), 1.34 (s, 9H). ¹³C NMR (101 MHz, CDCl₃): δ 171.6, 137.5, 131.0, 129.1, 128.6, 127.2, 126.1, 51.3, 37.3, 29.2, 28.9. The NMR data correspond to those described in literature.^[19]



N-phenyl-5-(*p*-tolyl)pent-4-enamide 5e was synthesized from (*E*)-5-(*p*-tolyl)pent-4-enoic acid S5e and aniline following general procedure C. 5e was obtained as beige powder (140.1 mg, 82% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.50 (d, *J* = 8.0 Hz, 2H), 7.31 (t, *J* = 8.0 Hz, 3H), 7.24 (d, *J* = 8.0 Hz, 2H), 7.11 – 7.08 (m, 3H), 6.46 (d, *J* = 15.8 Hz, 1H), 6.20 (dt, *J* = 15.8, 7.0 Hz, 1H), 2.63 (q, *J* = 7.1 Hz, 2H), 2.52 (t, *J* = 7.1 Hz, 2H), 2.33 (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 170.6, 137.9, 137.2, 134.6, 131.4, 129.4, 129.1, 127.6, 126.1, 124.4, 120.0, 37.5, 29.0, 21.3. HRMS (ESI+) m/z: calcd for $C_{18}H_{19}NaNO$ [M+Na]+: 288.1359, found 288.1368 (Δ = 3.1 ppm). IR (neat, cm⁻¹): v 3290, 2910, 2850, 1650, 1600, 1500, 1440.


5-(4-methoxyphenyl)-*N*-phenylpent-4-enamide **5f** was synthesized from (*E*)-5-(*p*-methoxyphenyl)pent-4-enoic acid **S5f** and aniline following general procedure C. **5f** was obtained as beige powder (252.7 mg, 92% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.50 (d, *J* = 8.0 Hz, 2H), 7.33 – 7.26 (m, 5H), 7.11 (t, *J* = 7.4 Hz, 1H), 6.84 (d, *J* = 8.7 Hz, 2H), 6.44 (d, *J* = 15.8 Hz, 1H), 6.12 (dt, *J* = 15.8, 6.8 Hz, 1H), 3.80 (s, 3H), 2.63 (q, *J* = 7.0 Hz, 2H), 2.52 (t, *J* = 7.0 Hz, 2H). ¹³C NMR (101 MHz, CDCl₃): δ 159.1, 130.9, 130.2, 129.2, 127.3, 126.4, 124.4, 120.0, 119.9, 114.1, 55.4, 48.9, 37.7, 29.0. HRMS (ESI+) m/z: calcd for C₁₈H₁₉NaNO₂ [M+Na]⁺: 304.1308, found 304.1316 (Δ = 2.6 ppm). IR (neat, cm⁻¹): v 3290, 2910, 1660, 1600, 1510, 1440, 1250, 1180.




N-phenyl-5-(4-(trifluoromethyl)phenyl)pent-4-enamide 5g was synthesized from (*E*)-5-(*p*-(trifluoromethyl)phenyl)pent-4-enoic acid S5g and aniline following general procedure C. 5g was obtained as beige powder (172.7 mg, 66% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.54 (d, *J* = 8.2 Hz, 2H), 7.50 (d, *J* = 8.0 Hz, 2H), 7.42 (d, *J* = 8.2 Hz, 2H), 7.32 (t, *J* = 8.0 Hz, 2H), 7.16 (brs, 1H), 7.11 (t, *J* = 7.4 Hz, 1H), 6.52 (d, *J* = 16.0 Hz, 1H), 6.37 (dt, *J* = 16.0, 7.0 Hz, 1H), 2.68 (q, *J* = 7.4 Hz, 2H), 2.55 (t, *J* = 7.4 Hz, 2H). ¹³C NMR (101 MHz, CDCl₃): δ 170.3, 140.9, 137.7, 131.5, 130.2, 129.2, 129.2 (q, *J* = 32.1 Hz), 126.3, 125.6 (q, *J* = 3.8 Hz), 124.5, 124.3 (q, *J* = 271.6 Hz), 120.0, 37.1, 28.8. ¹⁹F NMR

(377 MHz, CDCl₃): δ -62.97. **HRMS** (ESI+) m/z: calcd for C₁₈H₁₆F₃NaNO [M+Na]⁺: 342.1076, found 342.1085 (Δ = 2.6 ppm). **IR** (neat, cm⁻¹): v 3300, 1650, 1510, 1320, 1160, 1110, 1070.


5-(4-chlorophenyl)-*N*-phenylpent-4-enamide **5h** was synthesized from (*E*)-5-(*p*-chlorophenyl)pent-4-enoic acid **S5h** and aniline following general procedure C. **5h** was obtained as beige powder (257.1 mg, 95% yield). ¹H NMR (400 MHz, CDCl₃): δ 7.52 (d, *J* = 7.8 Hz, 2H), 7.45 (brs, 1H), 7.36 – 7.28 (m, 6H), 7.12 (t, *J* = 7.4 Hz, 1H), 6.43 (d, *J* = 15.8 Hz, 1H), 6.24 (dt, *J* = 15.8, 6.8 Hz, 1H), 2.64 (q, *J* = 7.1 Hz, 2H), 2.54 (t, *J* = 7.1 Hz, 2H). ¹³C NMR (101 MHz, CDCl₃): δ 170.5, 137.9, 135.9, 132.9, 130.2, 129.4, 129.1, 128.8, 127.4, 124.5, 120.0, 37.2, 28.8. HRMS (ESI+) m/z: calcd for C₁₇H₁₆³⁵ClNaNO [M+Na]⁺: 308.0813, found 308.0815 (Δ = 0.6 ppm). IR (neat, cm⁻¹): v 3290, 1650, 1600, 1520, 1500, 1440, 1095, 750.




2-(chloro(phenyl)methyl)-3,3,3-trifluoro-N-phenylpropanamide 2a was synthesized from N-(phenyl)cinnamamide **1a** following general procedure D and purified by silica gel flash chromatography eluting with petroleum ether/ethyl acetate (7/3). 2a was obtained as white solid (68.8 mg, 70% yield, d.r. = 96:4). R_f (in petroleum ether/ethyl acetate = 7/3): 0.32. ¹H NMR (400 MHz, (CD₃)₂SO): δ 10.69 (s, 0.75H, major diastereoisomer), 10.30 (s, 0.20H, minor diastereoisomer), 7.70 (d, J = 7.6 Hz, 1.61H, mixture of major and minor diastereoisomers), 7.60 (d, J = 7.2 Hz, 1.47 H, mixture of major and minor diastereoisomers), 7.58 - 7.54 (m, 0.52 H, minor)diastereoisomer), 7.49 - 7.18 (m, 6.32H, mixture of major and minor diastereoisomers), 7.14 (m, 0.81H, major diastereoisomer), 7.02 (m, 0.29H, minor diastereoisomer), 5.66 (d, J = 11.1 Hz, 0.76H, major diastereoisomer), 5.62 (d, J = 11.1 Hz, 1H, minor diastereoisomer), 4.59 – 4.38 (m, 1.06H, mixture of major and minor diastereoisomers). ¹³C NMR (101 MHz, (CD₃)₂SO): δ 162.5 (q, J = 2.2 Hz), 161.6 (q, J = 2.5 Hz), 138.0, 137.7, 137.6, 137.3, 129.3, 129.1, 128.8, 128.8, 128.6, 127.9, 124.5, 124.4, 124.4 (q, / = 282.3 Hz), 123.4 (q, / = 282.6 Hz), 119.7, 119.6, 58.4, 58.4, 57.7 (q, / = 24.2 Hz), 57.3 (q, J = 24.8 Hz). ¹⁹**F NMR** (377 MHz, (CD₃)₂SO): δ -62.81 (d, J = 7.9 Hz, major diastereoisomer), -62.97 (d, I = 7.6 Hz, minor diastereoisomer). HRMS (ES+) m/z: calcd for C₁₆H₁₄³⁵ClF₃NO [M+H]⁺: 328.0716, found 328.0723 (Δ = 2.1 ppm). **IR** (neat, cm⁻¹): v 3438, 3319, 3196, 1684, 1247, 1168, 1113,700.




N-benzyl-2-(chloro(phenyl)methyl)-3,3,3-trifluoropropanamide 2b was synthesized from N-(benzyl)cinnamamide **1b** following general procedure D and purified by silica gel flash chromatography eluting with petroleum ether/ethyl acetate (8/2). 2b was obtained as white solid (68.7 mg, 67% yield, d.r. = 72:28). R_f (in petroleum ether/ethyl acetate = 8/2): 0.27. ¹H NMR (400 MHz, (CD₃)₂SO): δ 9.02 (t, *J* = 5.6 Hz, 0.77H, major diastereoisomer), 8.72 (t, *J* = 5.8 Hz, 0.24H, minor diastereoisomer), 7.57 - 7.23 (m, 9.37H, mixture of major and minor diastereoisomers), 7.13 (m, 0.79H, major diastereoisomer), 5.52 (d, I = 11.1 Hz, 0.71H, major diastereoisomer), 5.48 (d, I =11.1 Hz, 0.28H, minor diastereoisomer), 4.44 (qd, *J* = 15.2, 5.8 Hz, 1.62H, mixture of major and minor diastereoisomers), 4.37 – 4.15 (m, 1.31H, mixture of major and minor diastereoisomers). ¹³**C NMR** (101 MHz, $(CD_3)_2$ SO and $CDCl_3$): δ 163.8 (q, *J* = 2.5 Hz), 162.9 (q, *J* = 2.5 Hz), 138.3, 137.8, 129.2, 129.1, 128.7, 128.6, 128.4, 128.2, 128.0, 127.8, 127.4, 127.1, 124.3 (q, *J* = 282.2 Hz), 123.4 (q, l = 282.2 Hz), 58.3 (q, l = 2.0 Hz), 57.5 (q, l = 2.0 Hz), 56.7 (q, l = 24.0 Hz)42.6, 41.9. ¹⁹**F NMR** (377 MHz, (CD₃)₂SO): δ -62.17 (d, *J* = 8.0 Hz, major diastereoisomer), -62.35 (d, J = 8.0 Hz, minor diastereoisomer). **HRMS** (ESI+) m/z: calcd for C₁₇H₁₅³⁵ClF₃NaNO [M+Na]+: 364.0686, found 364.0693 (Δ = 1.9 ppm). **IR** (neat, cm⁻¹): v 3295, 1656, 1620, 1553, 1454, 1315, 1161, 1120, 694.




2-(chloro(phenyl)methyl)-3,3,3-trifluoro-*N***-methylpropanamide 2c** was synthesized from *N*-(methyl)cinnamamide **1c** following general procedure D and purified by silica gel flash chromatography eluting with petroleum ether/ethyl acetate (6/4). **2c** was obtained as white solid (39.8 mg, 50% yield, d.r. = 73:36). R_f (in petroleum ether/ethyl acetate = 6/3): $0.31.^{[20]}$ ¹**H** NMR (400 MHz, (CD₃)₂SO): δ 8.47 (d, *J* = 4.4 Hz, 1H), 7.52 (m, 2H), 7.44 – 7.37 (m, 3H), 5.47 (d, *J* = 11.1 Hz, 1H), 4.21 (dq, *J* = 11.1, 8.1 Hz, 1H), 2.72 (d, *J* = 4.7 Hz, 3H). ¹³**C** NMR (101 MHz, (CD₃)₂SO): δ 164.2 (q, *J* = 2.4 Hz), 137.8, 129.2, 128.7, 127.8, 123.4 (q, *J* = 282.1 Hz), 58.3 (q, *J* = 2.0 Hz), 56.6 (q, *J* = 24.1 Hz), 25.9. ¹⁹**F** NMR (377 MHz, (CD₃)₂SO): δ -64.08 (d, *J* = 8.1 Hz), -64.09 (minor diastereoisomer, not isolated). **HRMS** (AP-) m/z: calcd for C₁₁H₁₁³⁵ClF₃NO [M]+: 265.0481, found 265.0472 (Δ = -3.4 ppm). **IR** (neat, cm⁻¹): v 3291, 3118, 1657, 1241, 1169, 1126.




N-(*tert*-butyl)-2-(chloro(phenyl)methyl)-3,3,3-trifluoropropanamide 2d was synthesized from *N*-(*tert*-butyl)cinnamamide 1d following general procedure D and purified by silica gel flash chromatography eluting with petroleum ether/ethyl acetate (8/2). 2d was obtained as white solid (52.6 mg, 57% yield, d.r. = 59:41). R_f (in petroleum ether/ethyl acetate = 8/2): 0.35. ¹H NMR (400 MHz, CDCl₃): δ 7.44 – 7.31 (m, 5H, mixture of major and minor diastereoisomers), 5.66 (brs, 0.46H, minor diastereoisomer), 5.39 (d, *J* = 10.4 Hz, 0.48H, minor diastereoisomer), 5.30 (d, *J* = 10.4 Hz, 0.48H, major diastereoisomer), 5.06 (brs, 0.48H, major diastereoisomer), 3.46 – 3.39 (m, 0.57H, major diastereoisomer), 5.03 (m, 0.51H, minor diastereoisomer), 1.43 (s, 4.56H, major diastereoisomer), 0.99 (s, 4.36H, minor diastereoisomer). ¹³C NMR (101 MHz, (CD₃)₂SO): δ 162.9 (q, *J* = 2.3 Hz), 161.9 (q, *J* = 2.5 Hz), 138.0, 137.7, 129.6, 129.1, 128.9, 128.3, 127.8, 127.8, 124.5 (q, *J* = 281.1 Hz), 123.6 (q, *J* = 282.4 Hz), 58.6 (q, *J* = 1.6 Hz), 57.9 (q, *J* = 2.3 Hz), 56.6 (q, *J* = 24.0 Hz), 56.6 (q, *J* = 24.0 Hz), 51.0, 50.4, 28.1, 27.5. ¹⁹F NMR (282 MHz, CDCl₃): δ -64.17 (d, *J* = 7.0 Hz, major diastereoisomer), -64.09 (d, *J* = 7.5 Hz, minor diastereoisomer). HRMS (AP-) m/z: calcd for C₁₄H₁₇³⁵ClF₃NO [M]⁺: 307.0951, found 307.0946 (Δ = -1.6 ppm). IR (neat, cm⁻¹): v 3308, 2980, 1657, 1366, 1334, 1241, 1165, 1120.




2-(chloro(phenyl)methyl)-3,3,3-trifluoropropanamide 2e was synthesized from cinnamamide **1e** following general procedure D and purified by silica gel flash chromatography eluting with petroleum ether/ethyl acetate (6/4). **2e** was obtained as white solid (203.8 mg, 81% yield, d.r. = 65:35). R_f (in petroleum ether/ethyl acetate = 6/4): $0.30.^{[20]}$ **1H** NMR (400 MHz, (CD₃)₂SO): δ 8.11 (brs, 1H), 7.79 (brs, 1H), 7.62 (m, 2H), 7.47 – 7.42 (m, 3H), 7.25 (d, *J* = 1.6 Hz, 1H). ¹³C NMR (101 MHz, (CD₃)₂SO): δ 164.4 (q, *J* = 1.0 Hz), 133.4 (q, *J* = 6.1 Hz), 132.3, 130.1, 129.3, 128.7, 126.4 (q, *J* = 29.6 Hz), 122.8 (q, *J* = 273.2 Hz). ¹⁹F NMR (377 MHz, (CD₃)₂SO): δ -64.26 (d, *J* = 1.7 Hz), -64.29 (minor diastereoisomer, not isolated). HRMS (ES+) m/z: calcd for C₁₀H₉F₃NO [M+H-HCl]⁺: 216.0636, found 216.0636 (Δ = 0.0 ppm). **IR** (neat, cm⁻¹): v 3388, 3189, 1613, 1280, 1150, 1116, 1012.




Methyl (2-(chloro(phenyl)methyl)-3,3,3-trifluoropropanoyl)glycinate 2f was synthesized from methyl 2-cinnamamidoacetate 1f following general procedure D and purified by silica gel flash chromatography eluting with petroleum ether/ethyl acetate (7/3). 2f was obtained as white solid (32.0 mg, 33% yield, d.r. = 26:74). R_f (in petroleum ether/ethyl acetate = 7/3): 0.30.^[20] ¹H NMR (400 MHz, CDCl₃): δ 7.45 – 7.42 (m, 2H), 7.40 – 7.35 (m, 3H), 6.85 (t, *J* = 4.9 Hz, 1H), 5.43 (d, *J* = 10.5 Hz, 1H), 4.20 (d, *J* = 4.9 Hz, 2H), 3.83 – 3.75 (m, 4H). ¹³C NMR (101 MHz, CDCl₃): δ 169.9, 164.6 (q, *J* = 2.1 Hz), 137.2, 129.5, 128.9, 127.9, 122.9 (q, *J* = 282.5 Hz), 59.4 (q, *J* = 25.4 Hz), 58.2 (q, *J* = 1.4 Hz), 52.8, 41.9. ¹⁹F NMR (377 MHz, CDCl₃): δ -63.90 (minor diastereoisomer, not isolated), -63.98 (d, *J* = 7.2 Hz). HRMS (ES+) m/z: calcd for C₁₃H₁₃³⁵ClF₃NaNO₃ [M+Na]⁺: 346.0434, found 346.0431 (Δ = -0.9 ppm). IR (neat, cm⁻¹): v 3284, 1751, 1656, 1562, 1234, 1168, 1125, 698.




2-(chloro(*p*-tolyl)methyl)-3,3,3-trifluoropropanamide 2g was synthesized from 4-(methyl)cinnamamide 1g following general procedure D and purified by silica gel flash chromatography eluting with petroleum ether/ethyl acetate (7/3). 2g was obtained as white solid (39.1 mg, 49% yield, d.r. = 23:77). R_f (in petroleum ether/ethyl acetate = 7/3): 0.33.^[20] ¹H NMR (400 MHz, CDCl₃): δ 7.31 (d, *J* = 8.1 Hz, 2H), 7.19 (d, *J* = 8.1 Hz, 2H), 5.88 (brs, 2H), 5.38 (d, *J* = 10.2 Hz, 1H), 3.64 (dq, *J* = 10.2, 7.5 Hz, 1H), 2.36 (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 166.1, 139.6, 134.1, 129.6, 127.7, 122.9 (q, *J* = 282.0 Hz), 59.3 (q, *J* = 25.3 Hz), 58.1 (q, *J* = 1.8 Hz), 21.4. ¹⁹F NMR (377 MHz, CDCl₃): δ -63.70 (minor diastereoisomer, not isolated), -63.73 (d, *J* = 7.4 Hz). HRMS (ESI+) m/z: calcd for C₁₁H₁₁³⁵ClF₃NaNO [M+Na]⁺: 288.0373, found 288.0382 (Δ = 3.1 ppm). IR (neat, cm⁻¹): v 3442, 3323, 3194, 1683, 1327, 1243, 1165, 1109.



2-(chloro(*m***-tolyl)methyl)-3,3,3-trifluoropropanamide 2h** was synthesized from 3-(methyl)cinnamamide **1h** following general procedure D and purified by silica gel flash chromatography eluting with petroleum ether/ethyl acetate (7/3). **2h** was obtained as white solid (58.2 mg, 73% yield, d.r. = 26:75). R_f (in petroleum ether/ethyl acetate = 7/3): 0.33. ¹H NMR (400 MHz, (CD₃)₂SO): δ 7.93 (brs, 0.69H, minor diastereoisomer), 7.68 (brs, 0.93H, major diastereoisomer), 7.37 – 7.24 (m, 3.36H, mixture of major and minor diastereoisomers), 7.18 (m, 1.27H, mixture of major and minor diastereoisomers), 5.39 (d, J = 10.9 Hz, 0.66H, major diastereoisomer), 5.37 (d, J = 10.9 Hz, 0.32H, minor diastereoisomer), 4.27 – 4.16 (m, 1.06H, mixture of major and minor diastereoisomers), 2.32 (s, 2.40H, major diastereoisomer), 2.30 (s, 0.97H, minor diastereoisomer). ¹³C NMR (101 MHz, (CD₃)₂SO): δ 166.7 (q, J = 2.2 Hz), 165.9 (q, J = 2.6 Hz), 138.8, 137.8, 138.7, 137.0, 130.4, 130.2, 128.9, 128.8, 128.4, 128.4, 124.9, 124.7, 122.9 (q, J = 282.5 Hz), 122.9 (q, J = 282.5 Hz), 59.0 (q, J = 25.0 Hz), 58.9 (q, J = 26.0 Hz), 58.2 (q, J = 1.7 Hz), 57.0 (q, J = 2.3 Hz), 29.8, 21.5. ¹⁹F NMR (377 MHz, (CD₃)₂SO): δ -62.29 (d, J = 8.0 Hz, major diastereoisomer), -62.51 (d, J = 7.8 Hz, minor diastereoisomer). **HRMS** (ESI+) m/z: calcd for C₁₁H₁₁³⁵ClF₃NaNO [M+Na]⁺: 288.0373, found 288.0381 (Δ = 2.8 ppm). **IR** (neat, cm⁻¹): v 3450, 3319, 3278, 3187, 1683, 1608, 1411, 1325, 1243, 1168, 1116.




2-(chloro(*o*-tolyl)methyl)-3,3,3-trifluoropropanamide **2i** was synthesized from 2-(methyl)cinnamamide **1i** following general procedure D and purified by silica gel flash chromatography eluting with petroleum ether/ethyl acetate (7/3). **2i** was obtained as white solid (55.0 mg, 69% yield, d.r. = 38:62). R_f (in petroleum ether/ethyl acetate = 7/3): 0.33.^[20] **1H NMR** (400 MHz, (CD₃)₂SO): δ 8.01 (brs, 1H), 7.74 (brs, 1H), 7.48 (d, *J* = 7.8 Hz, 1H), 7.31 – 7.22 (m, 3H), 5.60 (d, *J* = 11.2 Hz, 1H), 4.37 (dq, *J* = 16.7, 8.2 Hz, 1H), 2.39 (s, 3H). ¹³C NMR (101 MHz, (CD₃)₂SO): δ 165.6 (q, *J* = 2.3 Hz), 135.5, 130.9, 129.1, 127.5, 126.5, 125.0, 123.5 (q, *J* = 282.2 Hz), 55.2 (q, *J* = 23.8 Hz), 18.6 (q, *J* = 4.7 Hz). ¹⁹F NMR (377 MHz, (CD₃)₂SO): δ -63.91 (minor diastereoisomer, not isolated), -63.93 (d, *J* = 9.2 Hz). **HRMS** (ESI+) m/z: calcd for C₁₁H₁₁³⁵ClF₃NaNO [M+Na]⁺: 288.0373, found 288.0378 (Δ = 1.7 ppm). **IR** (neat, cm⁻¹): v 3450, 3320, 3200, 1690, 1240, 1190, 1100, 750.




2-(chloro(4-methoxyphenyl)methyl)-3,3,3-trifluoropropanamide 2j was synthesized from 4-(methoxy)cinnamamide **1j** following general procedure D and purified by silica gel flash chromatography eluting with petroleum ether/ethyl acetate (7/3). **2j** was obtained as white solid (15.2 mg, 18% yield, d.r. = 88:12). R_f (in petroleum ether/ethyl acetate = 7/3): 0.29.^[20] **1H NMR**


(400 MHz, CDCl₃): δ 7.48 (d, *J* = 8.8 Hz, 2H), 7.16 (d, *J* = 1.1 Hz, 1H), 6.89 (d, *J* = 8.8 Hz, 2H), 6.16 (brs, 1H), 5.78 (brs, 1H), 3.83 (m, 4H). ¹³**C NMR** (101 MHz, CDCl₃): δ 165.7, 161.6, 136.4 (q, *J* = 6.0 Hz), 131.5, 124.2, 123.2 (q, *J* = 30.6 Hz), 122.7 (q, *J* = 272.8 Hz), 114.5, 55.5. ¹⁹**F NMR** (377 MHz, CDCl₃): δ -64.31 (d, *J* = 1.6 Hz), -64.40 (minor diastereoisomer, not isolated). **HRMS** (EI+) m/z: calcd for C₁₁H₁₀F₃NO₂ [M-HCl]⁺: 245.06636, found 245.06628 (Δ = -0.3 ppm). **IR** (neat, cm⁻¹): v 3386, 3185, 1605, 1284, 1256, 1182, 1150, 1105.




2-(chloro(4-formylphenyl)methyl)-3,3,3-trifluoropropanamide 2l was synthesized from 4-(formyl)cinnamamide **1l** following general procedure D and purified by silica gel flash chromatography eluting with petroleum ether/ethyl acetate (7/3). **2l** was obtained as white solid (55.4 mg, 66% yield, d.r. = 56:44). R_f (in petroleum ether/ethyl acetate = 7/3): 0.31.^[20] **¹H** NMR (400 MHz, (CD₃)₂SO): δ 10.02 (s, 1H), 7.96 (d, *J* = 8.2 Hz, 3H), 7.76 (d, *J* = 8.2 Hz, 3H), 5.60 (d, *J* = 11.1 Hz, 1H), 4.29 (dq, *J* = 16.5, 8.2 Hz, 1H). ¹³C NMR (101 MHz, (CD₃)₂SO): δ 192.6, 165.1 (q, *J* = 2.3 Hz), 144.0, 136.5, 129.8, 128.7, 123.4 (q, *J* = 282.3 Hz), 57.2 (q, *J* = 1.7 Hz), 56.2 (q, *J* = 24.0 Hz). ¹⁹F NMR (377 MHz, (CD₃)₂SO): δ -64.07 (d, *J* = 8.2 Hz), -64.11 (minor diastereoisomer, not isolated). HRMS (EI+) m/z: calcd for C₁₁H₈F₃NO₂ [M-HCl]+: 243.05071, found 243.05101 (Δ = 1.2 ppm). **IR** (neat, cm⁻¹): v 3290, 3200, 1695, 1250, 1170, 1110.




Methyl 4-(2-carbamoyl-1-chloro-3,3,3-trifluoropropyl)benzoate 2m was synthesized from 4-(methoxycarbonyl)cinnamamide 1m following general procedure D and purified by silica gel flash chromatography eluting with petroleum ether/ethyl acetate (7/3). 2m was obtained as white solid (38.1 mg, 41% yield, d.r. = 73:27). R_f (in petroleum ether/ethyl acetate = 7/3): 0.35.^[20] ¹H NMR (400 MHz, (CD₃)₂SO): δ 8.00 (d, *J* = 7.7 Hz, 2H), 7.97 (brs, 1H), 7.74 (brs, 1H), 7.68 (d, *J* = 7.7 Hz, 2H), 5.57 (d, *J* = 11.1 Hz, 1H), 4.37 – 4.13 (m, 1H), 3.86 (s, 3H). ¹³C NMR (101 MHz, (CD₃)₂SO): δ 165.7, 165.2 (q, *J* = 2.2 Hz), 142.9, 130.3, 129.6, 128.3, 123.4 (q, *J* = 282.2 Hz), 57.2 (q, *J* = 1.2 Hz), 56.3 (q, *J* = 24.1 Hz), 52.3. ¹⁹F NMR (377 MHz, (CD₃)₂SO): δ -63.62 (d, *J* = 8.2 Hz), -63.70 (minor diastereoisomer, not isolated). HRMS (ESI+) m/z: calcd for C₁₂H₁₁³⁵ClF₃NaNO₃[M+Na]⁺: 322.0272, found 322.0283 (Δ = 3.4 ppm). IR (neat, cm⁻¹): v 3431, 3196, 1720, 1684, 1277, 1239, 1178, 1101.



2-(chloro(4-cyanophenyl)methyl)-3,3,3-trifluoropropanamide 2n was synthesized from 4-(cyano)cinnamamide **1n** following general procedure D and purified by silica gel flash chromatography eluting with petroleum ether/ethyl acetate (7/3). **2n** was obtained as white solid (21.6 mg, 26% yield, d.r. = 81:19). R_f (in petroleum ether/ethyl acetate = 7/3): 0.34.^[20] **1H NMR** (400 MHz, (CD₃)₂SO): δ 7.95 (brs, 1H), 7.92 (d, *J* = 8.4 Hz, 2H), 7.75 (d, *J* = 8.4 Hz, 3H), 5.63 (d, *J* = 11.1 Hz, 1H), 4.32 – 4.23 (dq, *J* = 11.1, 8.2 Hz, 1H). ¹³**C NMR** (101 MHz, (CD₃)₂SO): δ 165.0 (q, *J* = 2.2 Hz), 143.2, 132.8, 128.9, 123.4 (q, *J* = 282.1 Hz), 118.3, 111.9, 56.8 (q, *J* = 1.4 Hz), 56.0 (q, *J* = 24.3 Hz). ¹⁹**F NMR** (377 MHz, (CD₃)₂SO): δ -62.28 (d, *J* = 8.2 Hz), -68.48 (minor diastereoisomer, not isolated). **HRMS** (ESI+) m/z: calcd for C₁₁H₈³⁵ClF₃NaN₂O [M+Na]⁺: 299.0169, found 299.0170 (Δ = 0.3 ppm). **IR** (neat, cm⁻¹): v 3400, 3200, 2240, 1580, 1230, 1190, 1110.



2-(chloro(4-(trifluoromethyl)phenyl)methyl)-3,3,3-trifluoropropanamide 2o was synthesized from 4-(trifluoromethyl)cinnamamide **1o** following general procedure D and purified by silica gel flash chromatography eluting with petroleum ether/ethyl acetate (6/4). **2o** was obtained as white solid (29.7 mg, 31% yield, d.r. = 74:26). R_f (in petroleum ether/ethyl acetate = 6/4): 0.35.^[20] **1H NMR** (400 MHz, (CD₃)₂SO): δ 7.97 (brs, 1H), 7.81 (d, *J* = 8.5 Hz, 2H), 7.77 (d, *J* = 8.5 Hz, 2H), 7.74 (brs, 1H), 5.62 (d, *J* = 11.2 Hz, 1H), 4.33 – 4.24 (dq, *J* = 11.1, 8.2 Hz, 1H). ¹³**C NMR** (101 MHz, (CD₃)₂SO): δ 165.1 (q, *J* = 2.3 Hz), 142.5 (q, *J* = 1.2 Hz), 129.5 (q, *J* = 31.9 Hz), 128.8, 125.7 (q, *J* = 3.8 Hz), 123.9 (q, *J* = 272.3 Hz), 123.4 (q, *J* = 282.1 Hz), 56.9 (q, *J* = 1.3 Hz), 56.2 (q, *J* = 24.3 Hz). ¹⁹**F NMR** (377 MHz, (CD₃)₂SO): δ -62.47 (minor diastereoisomer, not isolated), -62.51, -63.55 (d, *J* = 8.2 Hz). **HRMS** (ESI+) m/z: calcd for C₁₁H₈³⁵ClF₆NaNO [M+Na]⁺: 342.0091, found 342.0096 (Δ = 1.5 ppm). **IR** (neat, cm⁻¹): v 3506, 3360, 1687, 1329, 1241, 1169, 1113, 1074, 1019.




2-(chloro(3-(trifluoromethyl)phenyl)methyl)-3,3,3-trifluoropropanamide 2p was synthesized from 3-(trifluoromethyl)cinnamamide 1p following general procedure D and purified by silica gel flash chromatography eluting with petroleum ether/ethyl acetate (6/4). 2p was obtained as white solid (33.6 mg, 35% yield, d.r. = 63:37). R_f (in petroleum ether/ethyl acetate = 6/4): 0.35.^[20] ¹**H** NMR (400 MHz, CDCl₃): δ 7.71 (s, 1H), 7.64 (d, *J* = 8.3 Hz, 1H), 7.61 (d, *J* = 9.2 Hz, 1H), 7.52 (t, *J* = 7.8 Hz, 1H), 6.28 (brs, 1H), 6.25 (brs, 1H), 5.46 (d, *J* = 10.4 Hz, 1H), 3.74 (dq, *J* = 10.4, 7.4 Hz, 1H). ¹³**C** NMR (101 MHz, CDCl₃): δ 166.5 (q, *J* = 2.2 Hz), 138.5, 131.9 (q, *J* = 32.51 Hz), 131.6, 129.9, 126.8 (q, *J* = 3.6 Hz), 124.1 (q, *J* = 272.0 Hz), 125.1 (q, *J* = 3.7 Hz), 123.0 (q, *J* = 282.3 Hz), 59.3 (q, *J* = 25.5 Hz), 57.5 (q, *J* = 1.7 Hz). ¹⁹**F** NMR (377 MHz, CDCl₃): δ -63.28 (minor diastereoisomer, not isolated), -63.35, -64.08 (d, *J* = 7.4 Hz), -64.26 (minor diastereoisomer, not isolated). HRMS (ES+) m/z: calcd for C₁₁H₈³⁵ClF₆NO [M]⁺: 319.01986, found 319.02101 (Δ = 1.1 ppm). **IR** (neat, cm⁻¹): v 3460, 3195, 1680, 1320, 1250, 1180, 1110, 1070.


3-chloro-2-(trifluoromethyl)pentanamide 2q was synthesized from (*E*)-hex-2-enamide **1q** following general procedure D and purified by silica gel flash chromatography eluting with petroleum ether/ethyl acetate (9.5/0.5). **2q** was obtained as white solid (26.1 mg, 31% yield, d.r. = 98:2). R_f (in petroleum ether/ethyl acetate = 9.5/0.5): $0.4^{[20]}$. **1H NMR** (400 MHz, CDCl₃): δ 8.42 (brs, 1H), 7.43 – 7.40 (m, 2H), 7.28 – 7.23 (m, 2H), 7.08 (tt, *J* = 7.5, 1.1 Hz, 1H), 4.78 (d, *J* = 1.2 Hz, 1H), 3.29 – 3.20 (m, 1H), 1.81 – 1.70 (m, 1H), 1.62 – 1.51 (m, 1H), 0.91 (td, *J* = 7.5, 0.8 Hz, 3H). ¹³**C NMR** (101 MHz, CDCl₃): δ 164.4, 136.6, 129.4, 126.9 (q, *J* = 280.8 Hz), 125.7, 120.3, 58.5 (q, *J* = 3.2 Hz), 46.9 (q, *J* = 25.9 Hz), 17.9 (q, *J* = 1.5 Hz), 11.8. ¹⁹**F NMR** (377 MHz, CDCl₃): δ -68.58 (d, *J* = 8.9 Hz). **HRMS** (EI+) m/z: calcd for C₁₂H₁₃³⁵ClF₃NO [M+Na]+: 279.06378, found 279.06487 (Δ = 3.9 ppm). **IR** (neat, cm⁻¹): v 3320, 3001, 1670, 1601, 1539, 1446, 1243, 1222, 1175, 1131, 1116, 1044, 735.

3-chloro-3-phenyl-2-(trifluoromethyl)acrylamide 2t was synthesized from 3-phenylpropiolamide **1t** following general procedure D and purified by silica gel flash chromatography eluting with petroleum ether/ethyl acetate (7/3). **2t** was obtained as white solid (29.2 mg, 39% yield). R_f (in petroleum ether/ethyl acetate = 7/3): 0.32. ¹H NMR (400 MHz, (CD₃)₂SO): δ 8.33 (brs, 1H), 7.95 (brs, 1H), 7.51 – 7.49 (m, 3H), 7.42 (m, 2H). ¹³C NMR (101 MHz, (CD₃)₂SO): δ 162.3 (q, *J* = 1.2 Hz), 140.7 (q, *J* = 4.6 Hz), 135.4, 130.3, 128.6, 127.5, 127.5 (q, *J* = 1.5 Hz), 121.0 (q, *J* = 274.4 Hz). ¹⁹F NMR (377 MHz, (CD₃)₂SO): δ -55.06. HRMS (ESI+) m/z: calcd for


C₁₀H₇³⁵ClF₃NaNO [M+Na]⁺: 272.0060, found 272.0068 (Δ = 2.9 ppm). **IR** (neat, cm⁻¹): v 3367, 3195, 1668, 1656, 1289, 1173, 1139, 1126, 639.




3-(chloro(phenyl)methyl)-4,4,4-trifluoro-*N***-phenylbutanamide 4a** was synthesized from *N*-phenyl-4-phenylbut-3-enamide **3a** following general procedure D and purified by silica gel flash chromatography eluting with petroleum ether/ethyl acetate (8/2). **4a** was obtained as white solid (54.3 mg, 53% yield, d.r. = 91:9). R_f(in petroleum ether/ethyl acetate = 8/2): 0.27.^[20] **1H NMR** (400 MHz, (CD₃)₂SO): δ 10.14 (s, 1H), 7.55 (d, *J* = 7.4 Hz, 2H), 7.48 (d, *J* = 7.4 Hz, 2H), 7.34 (m, 3H), 7.27 (t, *J* = 7.9 Hz, 2H), 7.03 (t, *J* = 7.4 Hz, 1H), 5.71 (d, *J* = 4.5 Hz, 1H), 3.74 – 3.64 (m, 1H), 2.88 – 2.77 (m, 2H). ¹³**C NMR** (101 MHz, (CD₃)₂SO): δ 167.2, 138.8, 138.1, 128.7, 128.6, 128.5, 127.4, 126.6 (q, *J* = 281.3 Hz), 123.4, 119.2, 59.6 (q, *J* = 2.5 Hz), 46.08 (q, *J* = 25.0 Hz), 31.60. ¹⁹**F NMR** (282 MHz, CDCl₃): δ -66.69 (d, *J* = 8.6 Hz), -72.12 (minor diastereoisomer, not isolated). **HRMS** (ESI+) m/z: calcd for C₁₇H₁₅³⁵ClF₃NaNO [M+Na]⁺: 364.0686, found 364.0683 (Δ = 0.8 ppm). **IR** (neat, cm⁻¹): v 3312, 2924, 2853, 1666, 1599, 1545, 1271, 1246, 1150, 1103.



N-benzyl-3-(chloro(phenyl)methyl)-4,4,4-trifluorobutanamide 4b was synthesized from *N*-benzyl-4-phenylbut-3-enamide 3b following general procedure D and purified by silica gel flash chromatography eluting with petroleum ether/ethyl acetate (8/2). 4b was obtained as white solid (43.8 mg, 41% yield, d.r. >98:2). R_f (in petroleum ether/ethyl acetate = 8/2): 0.29. ¹H NMR (400 MHz, CDCl₃): δ 7.37 (d, *J* = 7.0 Hz, 2H), 7.32 – 7.19 (m, 6H), 7.14 (d, *J* = 7.0 Hz, 2H), 5.90 (brs, 1H), 5.30 (d, *J* = 4.3 Hz, 1H), 4.33 – 4.18 (m, 2H), 3.68 – 3.58 (m, 1H), 2.62 (dd, *J* = 16.0, 4.2 Hz, 1H), 2.50 (dd, *J* = 16.0, 7.1 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃): δ 168.9, 138.2, 137.8, 128.8, 128.8, 127.9, 127.7, 127.2, 126.3 (q, *J* = 281.6 Hz), 59.7 (q, *J* = 2.7 Hz), 47.1 (q, *J* = 25.5 Hz), 44.0, 31.8 (q, *J* = 1.6 Hz). ¹⁹F NMR (377 MHz, CDCl₃): δ -68.82 (d, *J* = 8.6 Hz). HRMS (ES+) m/z: calcd for C₁₈H₁₈³⁵ClF₃NO [M+H]⁺: 356.1029, found 356.1026 (Δ = -0.3 ppm). IR (neat, cm⁻¹): v 3278, 2900, 1642, 1545, 1347, 1237, 1150, 1079, 954, 695.




3-(chloro(phenyl)methyl)-4,4,4-trifluoro-*N***-methylbutanamide 4c** was synthesized from *N*-methyl-4-phenylbut-3-enamide **3c** following general procedure D and purified by silica gel flash chromatography eluting with petroleum ether/ethyl acetate (7/3). **4c** was obtained as white solid (41.1 mg, 49% yield, d.r. = 88:12). R_f (in petroleum ether/ethyl acetate = 7/3): 0.26.^[20] **1H NMR** (400 MHz, (CD₃)₂SO): δ 7.97 (brs, 1H), 7.48 (d, *J* = 7.4 Hz, 2H), 7.40 – 7.29 (m, 3H), 5.61 (d, *J* = 4.3 Hz, 1H), 3.62 – 3.51 (m, 1H), 2.47 (m, 5H). ¹³**C NMR** (101 MHz, (CD₃)₂SO): δ 168.6, 138.1, 128.5, 128.4, 127.4, 126.5 (q, *J* = 282.4 Hz), 59.6 (q, *J* = 2.4 Hz), 46.2 (q, *J* = 24.6 Hz), 30.4 (q, *J* = 1.4 Hz), 25.6. ¹⁹**F NMR** (377 MHz, (CD₃)₂SO): δ -68.72 (d, *J* = 9.1 Hz), -72.23 (minor diastereoisomer, not isolated). **HRMS** (ES+) m/z: calcd for C₁₂H₁₄³⁵ClF₃NO [M+H]⁺: 280.0716, found 280.0707 (Δ = -3.2 ppm). **IR** (neat, cm⁻¹): v 3290, 3110, 2940, 1640, 1580, 1390, 1245, 1160, 1110, 995, 700.




N-(tert-butyl)-3-(chloro(phenyl)methyl)-4,4,4-trifluorobutanamide 4d was synthesized from *N*-tert-butyl-4-phenylbut-3-enamide 3d following general procedure D and purified by silica gel flash chromatography eluting with petroleum ether/ethyl acetate (8/2). 4d was obtained as white solid (52.1 mg, 54% yield, d.r. = 96:4). R_f (in petroleum ether/ethyl acetate = 8/2): 0.33.^[20] ¹H NMR (300 MHz, CDCl₃): δ 7.34 – 7.15 (m, 5H), 5.25 (d, *J* = 4.3 Hz, 2H), 3.57 – 3.45 (m, 1H), 2.45 (dd, *J* = 15.7, 4.3 Hz, 1H), 2.33 (dd, *J* = 15.7, 7.2 Hz, 1H), 1.16 (s, 9H). ¹³C NMR (75 MHz, CDCl₃): δ 168.1, 167.7, 138.3, 128.9, 128.8, 127.2, 126.5 (q, *J* = 281.4 Hz), 59.8 (q, *J* = 2.7 Hz), 51.6, 47.2 (q, *J* = 25.5 Hz), 32.7 (q, *J* = 1.5 Hz), 28.7. ¹⁹F NMR (282 MHz, CDCl₃): δ -68.80 (d, *J* = 8.6 Hz), -72.10 (minor diastereoisomer, not isolated). HRMS (ES+) m/z: calcd for C₁₅H₂₀³⁵ClF₃NO [M+H]⁺: 322.1186, found 322.1178 (Δ = -2.5 ppm). IR (neat, cm⁻¹): v 3303, 1670, 1601, 1539, 1446, 1375, 1289, 1276, 1243, 1222, 1175, 1131, 1116, 1091, 1044, 735.

CI CF₃ O

3-(chloro(phenyl)methyl)-4,4,4-trifluorobutanamide 4e was synthesized from 4-phenylbut-3-enamide **3e** following general procedure D and purified by silica gel flash chromatography eluting with petroleum ether/ethyl acetate (7/3). **4e** was obtained as white solid (44.6 mg, 56% yield, d.r. = 79:21). R_f (in petroleum ether/ethyl acetate = 7/3): 0.36.^[20] ¹**H** NMR (300 MHz, CDCl₃): δ 7.45 – 7.26 (m, 5H), 5.84 (brs, 1H), 5.63 (brs, 1H), 5.34 (d, *J* = 4.6 Hz, 1H), 3.67 – 3.58 (m, 1H), 2.69 (dd, *J* = 16.5, 4.1 Hz, 1H), 2.59 (dd, *J* = 16.5, 7.0 Hz, 1H). ¹³**C** NMR (75 MHz, CDCl₃): δ 171.4, 138.2, 128.9, 128.9, 127.2, 126.3 (q, *J* = 281.5 Hz), 59.7 (q, *J* = 2.8 Hz), 47.0 (q, *J* = 25.7 Hz), 31.1 (q, *J* = 1.7 Hz). ¹⁹**F** NMR (282 MHz, CDCl₃): δ -68.33 (d, *J* = 8.6 Hz), -72.14 (minor diastereoisomer, not isolated). HRMS (AP-) m/z: calcd for C₁₁H₁₁³⁵ClF₃NO [M]+: 265.0481, found 265.0475 (Δ = -2.3 ppm). **IR** (neat, cm⁻¹): v 3290, 2967, 1788, 1272, 1165, 1115, 1000, 698.




3-(chloro(*p*-tolyl)methyl)-4,4,4-trifluoro-*N*-phenylbutanamide 4f was synthesized from *N*-phenyl-4-(p-tolyl)but-3-enamide 3f following general procedure D and purified by silica gel flash chromatography eluting with petroleum ether/ethyl acetate (8/2). 4f was obtained as white solid (51.2 mg, 48% yield, d.r. = 83:17). R_f (in petroleum ether/ethyl acetate = 8/2): 0.28.^[20] 1H NMR (400 MHz, (CD₃)₂SO): δ 10.11 (s, 1H), 7.47 (d, *J* = 7.8 Hz, 2H), 7.43 (d, *J* = 7.8 Hz, 2H), 7.27 (t, *J* = 7.9 Hz, 2H), 7.18 (s, 1H), 7.16 (s, 1H), 7.03 (t, *J* = 7.4 Hz, 1H), 5.67 (d, *J* = 4.5 Hz, 1H), 3.70 – 3.62 (m, 1H), 2.82 – 2.75 (m, 2H), 2.25 (s, 3H). ¹³C NMR (101 MHz, (CD₃)₂SO): δ 167.2, 138.8, 138.0, 135.1, 129.0, 128.6, 127.2, 126.5 (q, *J* = 281.6 Hz), 123.3, 119.2, 59.6 (q, *J* = 2.3 Hz), 46.2 (q, *J* = 24.9 Hz), 31.6, 20.6. ¹⁹F NMR (377 MHz, (CD₃)₂SO): δ -66.69 (d, *J* = 9.1 Hz), -72.14 (minor diastereoisomer, not isolated). HRMS (ESI+) m/z: calcd for C₁₈H₁₇³⁵ClF₃NaNO [M+Na]⁺: 378.0843, found 378.0859 (Δ = 4.2 ppm). IR (neat, cm⁻¹): v 3300, 1660, 1550, 1250, 1150, 1100.




3-(chloro(*p*-methoxyphenyl)methyl)-4,4,4-trifluoro-*N*-phenylbutanamide 4g was synthesized from 4-(4-methoxyphenyl)-*N*-phenylbut-3-enamide 3g following general procedure D and purified by silica gel flash chromatography eluting with petroleum ether/ethyl acetate (7/3). 4g was obtained as white solid (68.0 mg, 61% yield, d.r. >98:2). R_f(in petroleum ether/ethyl acetate = 7/3): 0.31. ¹H NMR (400 MHz, (CD₃)₂SO): δ 7.40 (d, *J* = 7.6 Hz, 2H), 7.30 (d, *J* = 8.7 Hz, 2H), 7.25 (t, *J* = 7.9 Hz, 2H), 7.07 (t, *J* = 7.4 Hz, 1H), 6.85 (d, *J* = 8.7 Hz, 2H), 5.50 (d, *J* = 5.4 Hz, 1H), 3.68 (m, 4H), 3.10 (dd, *J* = 17.4, 9.9 Hz, 1H), 2.69 (dd, *J* = 17.4, 6.6 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃): δ 171.0, 159.8, 137.3, 131.2, 129.1, 127.4, 126.7 (q, *J* = 278.0 Hz), 126.1, 123.2, 114.9, 63.2 (q, *J* = 2.8 Hz), 55.4, 45.3 (q, *J* = 28.3 Hz), 31.1 (q, *J* = 2.1 Hz).¹⁹F NMR (377 MHz, (CD₃)₂SO): δ -70.35


(d, *J* = 9.3 Hz). **HRMS** (ESI+) m/z: calcd for C₁₈H₁₇³⁵ClF₃NaNO₂ [M+Na]⁺: 394.0792, found 394.0800 (Δ = 2.0 ppm). **IR** (neat, cm⁻¹): v 3300, 2960, 1650, 1600, 1500, 1440, 1250, 1150, 1110.




3-(chloro(*p*-(trifluoromethyl)phenyl)methyl)-4,4,4-trifluoro-*N*-phenylbutanamide 4h was synthesized from 4-(4-trifluoromethyl)-*N*-phenylbut-3-enamide 3h following general procedure D and purified by silica gel flash chromatography eluting with petroleum ether/ethyl acetate (8/2). 4h was obtained as white solid (32.0 mg, 26% yield, d.r. >98:2). R_f(in petroleum ether/ethyl acetate = 8/2): 0.27.^[20] ¹H NMR (400 MHz, (CD₃)₂SO): δ 10.09 (s, 1H), 7.80 (d, *J* = 8.3 Hz, 2H), 7.71 (d, *J* = 8.3 Hz, 2H), 7.41 (dd, *J* = 8.6, 1.0 Hz, 2H), 7.25 (t, *J* = 8.4 Hz, 2H), 7.02 (m, 1H), 5.87 (d, *J* = 4.3 Hz, 1H), 3.82 – 3.71 (m, 1H), 2.88 – 2.75 (m, 2H). ¹³C NMR (101 MHz, (CD₃)₂SO): δ 166.9, 142.3, 138.6, 129.0 (q, *J* = 31.9 Hz), 128.6, 128.4, 126.4 (q, *J* = 281.9 Hz), 125.3 (q, *J* = 3.6 Hz), 123.9 (q, *J* = 273.0 Hz), 123.4, 119.2, 58.7 (q, *J* = 2.2 Hz), 45.9 (q, *J* = 25.2 Hz), 31.3. ¹⁹F NMR (377 MHz, (CD₃)₂SO): δ -61.32, -66.74 (d, *J* = 9.2 Hz). HRMS (ESI+) m/z: calcd for C₁₈H₁₄³⁵ClF₆NaNO [M+Na]⁺: 432.0560, found 432.0576 (Δ = 3.7 ppm). IR (neat, cm⁻¹): v 3302, 1660, 1550, 1317, 1110, 1069.




4-(chloro(phenyl)methyl)-5,5,5-trifluoro-*N***-phenylpentanamide 6a** was synthesized from *N*-5-diphenylpent-4-enamide **5a** following general procedure D and purified by silica gel flash chromatography eluting with petroleum ether/ethyl acetate (8/2). **6a** was obtained as white solid (59.8 mg, 56% yield, d.r. = 91:9). R_f(in petroleum ether/ethyl acetate = 8/2): 0.28.^[20] **1H NMR** (400 MHz, (CD₃)₂SO): δ 9.93 (s, 1H), 7.55 – 7.53 (m, 4H), 7.37 (m, 3H), 7.27 (t, *J* = 7.9 Hz, 2H), 7.01 (t, *J* = 7.4 Hz, 1H), 5.62 (d, *J* = 4.7 Hz, 1H), 3.33 – 3.26 (m, 1H), 2.46 (d, *J* = 8.5 Hz, 1H), 2.34 (m, 1H), 2.03 (q, *J* = 7.1 Hz, 2H). ¹³**C NMR** (101 MHz, (CD₃)₂SO): δ 169.9, 139.1, 138.3, 128.6, 128.4, 127.4, 126.8 (q, *J* = 282.6 Hz), 123.1, 119.1, 60.1 (q, *J* = 3.0 Hz), 48.1 (q, *J* = 23.7 Hz), 33.0, 20.0. ¹⁹**F NMR** (377 MHz, (CD₃)₂SO): δ -65.15 (minor diastereoisomer, not isolated), -66.95 (d, *J* = 9.1 Hz). **HRMS** (ES+) m/z: calcd for C₁₈H₁₈³⁵ClF₃NO [M+H]⁺: 356.1031, found 356.1029 (Δ = 0.6 ppm). **IR** (neat, cm⁻¹): ν 3245, 3077, 1655, 1599, 1552, 1500, 1446, 1204, 1144, 1109, 752.



N-benzyl-4-(chloro(phenyl)methyl)-5,5,5-trifluoropentanamide 6b was synthesized from *N*-(benzyl)-5-phenylpent-4-enamide 5b following general procedure D and purified by silica gel flash chromatography eluting with petroleum ether/ethyl acetate (8/2). 6b was obtained as white solid (56.0 mg, 54% yield, d.r. = 95:5). R_f(in petroleum ether/ethyl acetate = 8/2): 0.30.^[20] ¹H NMR (300 MHz, CDCl₃): δ 7.40 – 7.15 (m, 10H), 5.77 (brs, 1H), 5.30 (d, *J* = 4.0 Hz, 1H), 4.34 – 4.20 (m, 2H), 2.82 – 2.77 (m, 1H), 2.24 – 2.06 (m, 4H). ¹³C NMR (75 MHz, CDCl₃): δ 171.2, 138.5, 138.2, 128.8, 128.7, 128.6, 127.9, 127.6, 127.2, 126.6 (q, *J* = 282.0 Hz), 59.8 (q, *J* = 3.3 Hz), 49.6 (q, *J* = 24.5 Hz), 43.6, 33.2, 20.2 (q, *J* = 1.3 Hz). ¹⁹F NMR (282 MHz, CDCl₃): δ -65.17 (minor diastereoisomer, not isolated), -66.86 (d, *J* = 8.7 Hz). HRMS (EI+) m/z: calcd for C₁₉H₁₉³⁵ClF₃NO [M]+: 369.11073, found 369.11166 (Δ = 2.5 ppm). IR (neat, cm⁻¹): v 3286, 1646, 1544, 1257, 1240, 1147, 1108, 1094, 695.




4-(chloro(phenyl)methyl)-5,5,5-trifluoro*N***-methylpentanamide 6c** was synthesized from *N*-(methyl)-5-phenylpent-4-enamide **5c** following general procedure D and purified by silica gel flash chromatography eluting with petroleum ether/ethyl acetate (7/3). **6c** was obtained as white solid (49.3 mg, 56% yield, d.r. >98:2). R_f (in petroleum ether/ethyl acetate = 7/3): 0.28. ¹H NMR (400 MHz, (CD₃)₂SO): δ 7.75 (brs, 1H), 7.52 (d, *J* = 7.2 Hz, 2H), 7.38 (m, 3H), 5.58 (d, *J* = 4.7 Hz, 1H), 3.27 – 3.16 (m, 1H), 2.51 (d, *J* = 4.5 Hz, 3H), 2.24 – 2.16 (m, 1H), 2.09 – 2.01 (m, 1H), 1.92 (q, *J* = 8.0 Hz, 2H). ¹³**C** NMR (101 MHz, (CD₃)₂SO): δ 171.2, 138.3, 128.4, 127.4, 126.8 (q, *J* = 282.6 Hz), 60.1 (q, *J* = 3.2 Hz), 48.1 (q, *J* = 23.7 Hz), 32.1, 25.4, 20.4 (q, *J* = 0.9 Hz). ¹⁹**F** NMR (377 MHz, (CD₃)₂SO): δ -66.56 (d, *J* = 9.1 Hz). **HRMS** (AP-) m/z: calcd for C₁₃H₁₅³⁵ClF₃NO [M]+: 293.0794, found 293.0792 (Δ = -0.7 ppm). **IR** (neat, cm⁻¹): v 3401, 1637, 1564, 1264, 1248, 1196, 1144, 1114, 1095, 1077, 1010, 697.




N-(tert-butyl)-4-(chloro(phenyl)methyl)-5,5,5-trifluoropentanamide 6d was synthesized from *N*-(*tert*-butyl)-5-phenylpent-4-enamide 5d following general procedure D and purified by

silica gel flash chromatography eluting with petroleum ether/ethyl acetate (8/2). **6d** was obtained as white solid (58.4 mg, 58% yield, d.r. = 91:9). R_f(in petroleum ether/ethyl acetate = 8/2): 0.34.^[20] ¹**H NMR** (400 MHz, (CD₃)₂SO): δ 7.52 – 7.50 (m, 2H), 7.43 – 7.33 (m, 4H), 5.57 (d, *J* = 4.6 Hz, 1H), 3.23 – 3.12 (m, 1H), 2.18 – 2.16 (m, 1H), 2.06 – 1.91 (m, 1H), 1.87 (dd, *J* = 14.4, 7.4 Hz, 2H), 1.19 (s, 9H). ¹³**C NMR** (101 MHz, (CD₃)₂SO): δ 170.3, 138.3, 128.4, 127.4, 126.8 (q, *J* = 282.0 Hz), 60.1 (q, *J* = 3.2 Hz), 49.8, 48.2 (q, *J* = 23.7 Hz), 32.7, 28.5, 20.4. ¹⁹**F NMR** (377 MHz, (CD₃)₂SO): δ -62.83 (minor diastereoisomer, not isolated), -64.87. **HRMS** (AP-) m/z: calcd for C₁₆H₂₁³⁵ClF₃NO [M]+: 335.1264, found 335.1251 (Δ = -3.9 ppm). **IR** (neat, cm⁻¹): v 3310, 2990, 1640, 1560, 1250, 1200, 1140, 1105, 1085.




4-(chloro(p-tolyl)methyl)-5,5,5-trifluoro-*N***-phenylpentanamide 6e** was synthesized from *N*-phenyl-5-(*p*-tolyl)pent-4-enamide **5e** following general procedure D and purified by silica gel flash chromatography eluting with petroleum ether/ethyl acetate (8/2). **6e** was obtained as orange oil (55.5 mg, 50% yield, d.r. = 95:5). R_f (in petroleum ether/ethyl acetate = 8/2): 0.29.^[20] **1H NMR** (400 MHz, (CD₃)₂SO): δ 9.88 (s, 1H), 7.50 (d, *J* = 8.1 Hz, 2H), 7.38 (d, *J* = 8.1 Hz, 2H), 7.23 (t, *J* = 8.0 Hz, 2H), 7.16 (d, *J* = 8.0 Hz, 2H), 6.97 (t, *J* = 7.4 Hz, 1H), 5.54 (d, *J* = 4.7 Hz, 1H), 3.21 (m, 1H), 2.46 (m, 2H), 2.25 (s, 3H), 1.98 (q, *J* = 7.4 Hz, 2H). ¹³**C NMR** (101 MHz, (CD₃)₂SO): δ 169.9, 139.1, 137.8, 135.4, 128.9, 128.6, 127.3, 126.9 (q, *J* = 282.5 Hz), 123.0, 119.1, 60.1 (q, *J* = 2.8 Hz), 48.2 (q, *J* = 23.6 Hz), 33.1, 20.6, 20.0. ¹⁹**F NMR** (377 MHz, (CD₃)₂SO): δ -64.36 (minor diastereoisomer, not isolated), -64.96 (d, *J* = 9.1 Hz). **HRMS** (ESI+) m/z: calcd for C₁₉H₁₉³⁵ClF₃NaNO [M+Na]+: 392.0999, found 392.1011 (Δ = 3.1 ppm). **IR** (neat, cm⁻¹): v 3300, 1660, 1600, 1550, 1440, 1250, 1167, 1108.




4-(chloro(4-methoxyphenyl)methyl)-5,5,5-trifluoro-*N***-phenylpentanamide** 6f was synthesized from 5-(4-methoxyphenyl)-*N*-phenylpent-4-enamide **5f** following general procedure D and purified by silica gel flash chromatography eluting with petroleum ether/ethyl acetate (8/2). **6f** was obtained as orange oil (64.8 mg, 56% yield, d.r. = 61:39). R_f (in petroleum ether/ethyl acetate = 8/2): 0.26.^[20] **1H NMR** (400 MHz, (CD₃)₂SO): δ 7.27 – 7.21 (m, 4H), 7.15 (tt, *J* = 7.4, 1.7 Hz, 1H), 7.03 – 7.01 (m, 2H), 6.89 – 6.86 (m, 2H), 5.09 (d, *J* = 5.0 Hz, 1H), 3.71 (s, 3H), 3.17 – 3.13 (m, 1H), 2.75 (dt, *J* = 17.6, 7.1 Hz, 1H), 2.55 – 2.47 (m, 2H), 2.06 (m, 2H). ¹³**C NMR** (101 MHz,

(CD₃)₂SO): δ 168.5, 158.7, 141.8, 131.4, 128.6, 128.4, 127.5, 127.2 (q, *J* = 282.0 Hz), 126.6, 113.9, 62.2 (d, *J* = 1.8 Hz), 55.0, 43.7 (q, *J* = 25.1 Hz), 29.2, 17.5 (q, *J* = 1.8 Hz). ¹⁹**F** NMR (377 MHz, (CD₃)₂SO): δ -69.00 (minor diastereoisomer, not isolated), -70.00 (d, *J* = 9.3 Hz). HRMS (ESI+) m/z: calcd for C₁₉H₁₉³⁵ClF₃NaNO₂ [M+Na]+: 408.0949, found 408.0954 (Δ = 1.2 ppm). IR (neat, cm⁻¹): ν 3304, 2937, 1661, 1601, 1543, 1442, 1247, 1154, 1109, 1031.




4-(chloro(4-(trifluoromethyl)phenyl)methyl)-5,5,5-trifluoro-*N***-phenylpentanamide 6g was synthesized from 5-(4-trifluoromethyl)-***N***-phenylpent-4-enamide 5g following general procedure D and purified by silica gel flash chromatography eluting with petroleum ether/ethyl acetate (8/2). 6g was obtained as colorless oil (66.1 mg, 52% yield, d.r. >98:2). R_f (in petroleum ether/ethyl acetate = 8/2): 0.28. ¹H NMR (400 MHz, CDCl₃): δ 7.59 (d,** *J* **= 8.3 Hz, 2H), 7.53 (d,** *J* **= 8.3 Hz, 2H), 7.38 (d,** *J* **= 7.8 Hz, 2H), 7.25 (t,** *J* **= 7.29 Hz, 3H), 7.07 (t,** *J* **= 7.4 Hz, 1H), 5.33 (d,** *J* **= 4.1 Hz, 1H), 2.96 – 2.86 (m, 1H), 2.44 (m, 1H), 2.31 (m, 1H), 2.21 – 2.12 (m, 2H). ¹³C NMR (101 MHz, CDCl₃): δ 169.6, 142.4, 137.6, 130.9 (q,** *J* **= 32.7 Hz), 129.1, 127.8, 126.5 (q,** *J* **= 282.1 Hz), 125.8 (q,** *J* **= 3.7 Hz), 124.7, 123.9 (q,** *J* **= 272.4 Hz), 120.1, 59.1 (q,** *J* **= 3.3 Hz), 49.3 (q,** *J* **= 24.7 Hz), 33.9, 20.0. ¹⁹F NMR (377 MHz, CDCl₃): δ -63.18, -66.55 (d,** *J* **= 8.6 Hz). HRMS (ESI+) m/z: calcd for C₁₉H₁₆³⁵ClF₆NaNO [M+Na]+: 446.0717, found 446.0724 (Δ = 1.6 ppm). IR (neat, cm⁻¹): v 3304, 2924, 1664, 1549, 1502, 1325, 1109, 1068, 750.**



4-(chloro(4-chlorophenyl)methyl)-5,5,5-trifluoro-*N*-phenylpentanamide 6h was synthesized from 5-(4-chloro)-*N*-phenylpent-4-enamide 5h following general procedure D and purified by silica gel flash chromatography eluting with petroleum ether/ethyl acetate (8/2). 6h was obtained as beige oil (49.2 mg, 42% yield, d.r. = 95:5). R_f (in petroleum ether/ethyl acetate = 8/2): 0.32.^[20] ¹H NMR (400 MHz, CDCl₃): δ 7.43 – 7.28 (m, 8H), 7.16 (brs, 1H), 7.11 (t, *J* = 7.4 Hz, 1H), 5.31 (d, *J* = 4.1 Hz, 1H), 2.92 – 2.84 (m, 1H), 2.49 – 2.15 (m, 4H). ¹³C NMR (101 MHz, CDCl₃): δ 169.8, 137.9, 137.4, 134.9, 129.5, 129.3, 129.0, 126.9 (q, *J* = 282.2 Hz), 124.9, 120.3, 59.5 (q, *J* = 3.2 Hz), 49.7 (q, *J* = 24.6 Hz), 34.4, 20.4. ¹⁹F NMR (377 MHz, CDCl₃): δ -65.13 (minor diastereoisomer, not isolated), -66.68 (d, *J* = 8.6 Hz). HRMS (ESI+) m/z: calcd for


C₁₈H₁₆³⁵Cl₂F₃NaNO [M+Na]⁺: 412.0453, found 412.0461 (Δ = 1.9 ppm). **IR** (neat, cm⁻¹): v 3315, 2926, 1664, 1601, 1543, 1493, 1442, 1250, 1187, 1150, 1116, 1092, 750.

2-((benzylamino)(*m***-tolyl)methyl)-3,3,3-trifluoropropanamide 7** was synthesized from 2-(chloro(*m*-tolyl)methyl)-3,3,3-trifluoropropanamide **2h**. A solution of **2h** (35.2 mg, 0.13 mmol, 1.0 equiv.) and benzylamine (28.9 μL, 0.26 mmol, 2.0 equiv.) in THF (883.0 μL, 150 mM) was stirred for 24 h at room temperature. Water and ethyl acetate were added and the solution was extracted 3 times with ethyl acetate. The organic layer was dried over MgSO₄ and concentrated under reduced pressure. The purification was carried out by silica gel flash chromatography eluting with petroleum ether/ethyl acetate (6/4). **7** was obtained as white solid (29.5 mg, 66% yield). R_{*f*} (in petroleum ether/ethyl acetate = 6/4): 0.31. ¹**H NMR** (400 MHz, (CD₃)₂SO): δ 7.68 (brs, 1H), 7.51 – 7.26 (m, 10H), 7.14 (brs, 1H), 4.16 (d, *J* = 10.5 Hz, 1H), 3.81 – 3.70 (m, 2H), 3.54 (s, 3H), 3.46 (d, *J* = 13.9 Hz, 1H). ¹³**C NMR** (101 MHz, (CD₃)₂SO): δ 166.5 (q, *J* = 2.6 Hz), 140.4, 140.0, 136.8, 128.8, 128.1, 128.0, 127.9, 127.8, 126.6, 125.3 (q, *J* = 281.0 Hz), 125.2, 59.2, 55.2 (q, *J* = 23.2 Hz), 49.8, 21.2. ¹⁹**F NMR** (377 MHz, (CD₃)₂SO): δ -62.01 (d, *J* = 8.4 Hz). **HRMS** (ESI+) m/z: calcd for C₁₈H₁₉F₃N₂O [M+H]⁺: 337.1522, found 337.1533 (Δ = 3.3 ppm). **IR** (neat, cm⁻¹): v 3410, 3320, 3200, 1670, 1250, 1140, 1120, 1100.



2-benzyl-3,3,3-trifluoropropanamide 8 was synthesized from 2-(chloro(phenyl)methyl)-3,3,3-trifluoropropanamide **2e**. A solution of **2e** (50.0 mg, 0.20 mmol, 1.0 equiv.) and zinc (19.5 mg, 0.30 mmol, 1.5 equiv.) in acetic acid (1.0 mL, 200 mM) was stirred during 3 h at 80 °C. After completion of the reaction, the solution was cooled down to room temperature and washed 5 times with water. The combined organic layers were dried over MgSO₄ and concentrated under reduced pressure. The purification was carried out by silica gel flash chromatography eluting with petroleum ether/ethyl acetate (6/4). **8** was obtained as white solid (29.3 mg, 68% yield). R_f (in petroleum ether/ethyl acetate = 6/4): 0.24. ¹**H NMR** (400 MHz, (CD₃)₂SO): δ 7.64 (brs, 1H), 7.32 – 7.28 (m, 3H), 7.24 – 7.21 (m, 3H), 3.56 – 3.45 (m, 1H), 3.08 (dd, *J* = 13.6, 10.9 Hz, 1H), 2.93 (dd, *J* = 13.6, 4.2 Hz, 1H). ¹³**C NMR** (101 MHz, (CD₃)₂SO): δ 166.6 (q, *J* = 2.6 Hz), 137.0, 128.8, 128.4, 126.7, 125.5 (q,

J = 279.9 Hz), 50.4 (q, *J* = 24.6 Hz), 31.1 (q, *J* = 2.5 Hz). ¹⁹**F NMR** (377 MHz, (CD₃)₂SO): δ -66.97 (d, *J* = 9.0 Hz). **HRMS** (ESI+) m/z: calcd for C₁₀H₁₀F₃NaNO [M+Na]⁺: 240.0607, found 240.0606 (Δ = 0.4 ppm). **IR** (neat, cm⁻¹): v 3390, 3210, 1650, 1250, 1150, 1110.



3-phenyl-2-(trifluoromethyl)acrylamide 9 was synthesized from 2-(chloro(phenyl)methyl)-3,3,3-trifluoropropanamide **2e**. A solution of **2e** (37.7 mg, 0.15 mmol, 1.0 equiv.) and sodium azide (14.6 mg, 0.23 mmol, 1.5 equiv.) in DMF (750 μL, 200 mM) was stirred during 3 h at 75 °C. After completion of the reaction, the solution was cooled down to room temperature and ethyl acetate and water were added. Organic layer was washed 5 times with water. The organic layer was dried over MgSO₄ and concentrated under reduced pressure. The purification was carried out by silica gel flash chromatography eluting with petroleum ether/ethyl acetate (7/3). **9** was obtained as white solid (23.4 mg, 73% yield). R_{*f*} (in petroleum ether/ethyl acetate = 7/3): 0.37. ¹**H NMR** (400 MHz, (CD₃)₂SO): δ 8.10 (brs, 1H), 7.79 (brs, 1H), 7.61 (m, 2H), 7.44 (m, 3H), 7.24 (brs, 1H). ¹³**C NMR** (101 MHz, (CD₃)₂SO): δ 164.4, 133.4 (q, *J* = 6.0 Hz), 132.3, 130.1, 129.3, 128.7, 126.4 (q, *J* = 29.6 Hz), 122.8 (q, *J* = 273.2 Hz). ¹⁹**F NMR** (377 MHz, (CD₃)₂SO): δ -64.74. **HRMS** (ESI+) m/z: calcd for C₁₀H₉F₃NO [M+H]⁺: 216.0636, found 216.0630 (Δ = -2.8 ppm). **IR** (neat, cm⁻¹): v 3393, 3191, 1637, 1441, 1278, 1116, 1008.

6. References

[1] T. Rawner, E. Lutsker, C. A. Kaiser and O. Reiser, *ACS Catal.*, 2018, **8**, 3950–3956.

[2] W. Shao, C. Besnard, L. Guénée and C. Mazet, J. Am. Chem. Soc., 2020, **142**, 16486–16492.

[3] E. Banfi, G. Scialino, C. Monti-Bragadin, *Journal of Antimicrobial Chemotherapy* 2003, **525**, 796–800.

[4] J. O'Brien, I. Wilson, T. Orton, F. Pognan, *European Journal of Biochemistry* 2000, **267 (17)**, 5421–5426.

[5] S. Ueda, T. Okada and H. Nagasawa, *Chem. Commun.*, 2010, **46**, 2462.

[6] P. V. Ramachandran and H. J. Hamann, *Org. Lett.*, 2021, **23**, 2938–2942.

[7] V. A. Sherstyuk, R. V. Ottenbacher, E. P. Talsi and K. P. Bryliakov, *ACS Catal.*, 2024, **14**, 498–507.

[8] Q. Fan, H. Jiang, E. Yuan, J. Zhang, Z. Ning, S. Qi and Q. Wei, *Food Chemistry*, 2012, **134**, 1081–1087.

[9] 이현승, Kim, Sung Hwan and Kim, Jae Nyoung, Bulletin of the Korean Chemical Society, 2011, **32**, 1748–1750.

[10] F. Panahi, N. Zarnaghash and A. Khalafi-Nezhad, *New J. Chem.*, 2016, **40**, 1250–1255.

[11] H. Ahn, I. Son, J. Lee and H. J. Lim, Asian Journal of Organic Chemistry, 2017, 6, 335–341.

[12] B. Bernardim and A. C. B. Burtoloso, *Tetrahedron*, 2014, **70**, 3291–3296.

[13] P. Fan, R. Wang and C. Wang, *Org. Lett.*, 2021, **23**, 7672–7677.

[14] G. Qiu, M. Mamboury, Q. Wang and J. Zhu, *Angewandte Chemie International Edition*, 2016, **55**, 15377–15381.

[15] M. K. Gupta, Z. Li and T. S. Snowden, Org. Lett., 2014, 16, 1602–1605.

[16] Y. Sato, Y. Miyamoto, T. Matsui, Y. Sumida and H. Ohmiya, *Chem Catalysis*, 2023, **3**.


[17] G. L. Hoang, S. Zhang and J. M. Takacs, *Chem. Commun.*, 2018, **54**, 4838–4841.


[18] J. Matsuoka, M. Terashita, A. Miyawaki, K. Tomioka and Y. Yamamoto, *Tetrahedron Letters*, 2022, **89**, 153599.

[19] H.-Q. Geng and X.-F. Wu, *Chem. Commun.*, 2022, **58**, 6534–6537.

[20] The yield and R_f were obtained only with the isolate diastereoisomer.

7. NMR spectra








0.0


4,5 8,5


110 100 f1 (ppm)































































³.35
³.35
³.35
³.33
³

